Immune System

can be indicative of rheumatoid arthritis (RA) and erosive psoriatic arthritis.

14-3-3 eta: a highly specific RA marker that adds ~15% diagnostic sensitivity beyond RF/anti-CCP; >0.50 ng/mL predicts faster radiographic progression.

21-Hydroxylase Antibody – What Does It Mean? 21-Hydroxylase Antibody is an autoantibody that targets 21-hydroxylase, a key enzyme involved in the production of cortisol and aldosterone in the adrenal glands. The presence of these antibodies is commonly associated with autoimmune adrenal insufficiency, particularly Addison’s disease. Why Is This Test Important? This test is primarily used to: - Diagnose autoimmune adrenal insufficiency (Addison’s disease) - Differentiate autoimmune causes of adrenal failure from other causes (e.g., infections, genetic conditions, or medication-induced adrenal suppression) - Identify individuals at risk for developing adrenal insufficiency, especially in people with other autoimmune diseases Symptoms of Autoimmune Adrenal Insufficiency If the antibodies are causing damage to the adrenal glands, individuals may experience: Chronic fatigue and weakness Weight loss and appetite loss Low blood pressure (hypotension) and dizziness Hyperpigmentation (darkening of the skin) due to increased ACTH levels Salt cravings due to aldosterone deficiency Low blood sugar (hypoglycemia) Final Thoughts A positive 21-hydroxylase antibody test is a key marker of autoimmune adrenal insufficiency and can help diagnose Addison’s disease before symptoms become severe. If your test is positive, further adrenal function testing is essential to assess whether hormone replacement therapy is needed.

This is the primary diagnostic test for myasthenia gravis.

What is Adenosine Deaminase (ADA)? Adenosine Deaminase (ADA) is an enzyme that plays a vital role in the breakdown of adenosine, a building block of DNA and RNA. This enzyme is essential for the proper development and function of the immune system, especially for T lymphocytes (T cells), which are white blood cells that help the body fight infections and diseases. Without sufficient ADA activity, toxic byproducts can accumulate and disrupt immune function. What does the “RBC” in the test name mean? The term RBC stands for Red Blood Cells. Measuring ADA specifically in red blood cells (as opposed to serum or other compartments) provides insight into how this enzyme is functioning within blood cell metabolism and may reflect longer-term or intracellular changes related to immune or hematologic conditions. Why is this test done? The Adenosine Deaminase, RBC test is used to evaluate conditions that affect immune function, red blood cell health, or chronic infections. Elevated or decreased ADA activity in RBCs may be associated with: Tuberculosis (TB) ADA levels are often elevated in TB, especially in pleural TB. While ADA in pleural fluid is more specific for TB diagnosis, ADA in RBCs may still support broader immune or infectious disease evaluations. Autoimmune or chronic inflammatory conditions Conditions like rheumatoid arthritis, lupus, or sarcoidosis may affect ADA levels due to chronic immune activation. Severe Combined Immunodeficiency (SCID) In rare cases, very low ADA activity may suggest a genetic ADA deficiency, a cause of SCID—a life-threatening immune disorder found in newborns. Leukemias and lymphomas Certain blood cancers may show abnormal ADA activity due to disrupted cell turnover and immune dysregulation. What does an elevated ADA in RBCs mean? An elevated Adenosine Deaminase (RBC) level may indicate: Increased T-cell activity or immune system stimulation Chronic infections, such as tuberculosis Autoimmune diseases (e.g., systemic lupus erythematosus or rheumatoid arthritis) Certain hematologic cancers (e.g., lymphoma or leukemia) Liver disease or other inflammatory states However, this marker is not disease-specific—an elevated result is a clue rather than a definitive diagnosis. What does a decreased ADA in RBCs mean? A low ADA level in red blood cells may suggest: ADA deficiency, a rare genetic disorder that leads to Severe Combined Immunodeficiency (SCID) in infants Impaired T-cell function, possibly from bone marrow suppression or immunosuppressive therapies Nutritional deficiencies affecting enzyme function In adults, mildly decreased levels are less common and may be of uncertain significance unless correlated with other findings. Here is a table summarizing the main conditions associated with abnormal Adenosine Deaminase (ADA) activity in red blood cells (RBCs): Condition ADA in RBCs Clinical Relevance Severe Combined Immunodeficiency (SCID) Decreased ADA deficiency is a genetic cause of SCID, leading to impaired lymphocyte development and function12345810. Diamond-Blackfan Anemia (DBA) Increased Elevated erythrocyte ADA is a supportive diagnostic marker for DBA, a congenital red cell aplasia7. Tuberculosis (especially pleural TB) Increased ADA is often elevated in TB, reflecting immune activation; more commonly measured in pleural fluid6. Autoimmune/Chronic Inflammatory Diseases Increased Conditions like lupus or rheumatoid arthritis can increase ADA due to chronic immune stimulation6. Hematologic Malignancies (Leukemia/Lymphoma) Increased Abnormal ADA activity may be seen due to disrupted cell turnover and immune dysregulation6. Bone Marrow Failure Syndromes (non-DBA) Variable Some inherited and acquired marrow failure syndromes may alter ADA, but less specifically than DBA7. Liver Diseases (e.g., hepatitis) Increased ADA may be elevated in various liver diseases due to inflammation or infection6. Nutritional Deficiencies Decreased Can impair enzyme function, leading to reduced ADA activity6. Note: ADA activity in RBCs is a supportive, not definitive, marker for these conditions. Results must always be interpreted in clinical context. How is this test used clinically? Physicians may order ADA in RBCs as part of a workup for: Chronic unexplained fatigue, fever, or weight loss Suspected tuberculosis (in combination with other TB-specific tests) Evaluation of immune deficiency or autoimmunity Monitoring of certain cancer types or treatments Investigation of abnormal red blood cell function Because ADA levels can be influenced by many different factors, this test is typically interpreted alongside other lab results and clinical findings. Key Takeaways Adenosine Deaminase, RBC helps assess immune activity and certain metabolic or infectious conditions. Elevated levels suggest immune activation, chronic inflammation, or infection. Low levels may indicate immune deficiency, including rare conditions like ADA-SCID. It’s a supportive test, not a standalone diagnostic tool—interpretation depends on clinical context. If you’ve received abnormal results for this test, speak with your healthcare provider to discuss what it may mean for your health and whether further testing is recommended.

Evaluating potential nephrotic syndrome and pancreatitis

Regulates pigmentation, appetite, and immune response.

Antinuclear antibody screen by indirect immunofluorescence with reflex to titer and pattern

detects antinuclear antibodies (ANA) in your blood

can give information about the type of autoimmune disease present

Explains what your ANA staining pattern may suggest.

can detect various autoimmunen diseases

can detect various autoimmunen diseases

ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A positive ANA IFA result is suggestive of autoimmune disease and reflexes to titer and pattern. Further laboratory testing may be considered if clinically indicated.

Autoimmune antibody screening

ANA stands for "Antinuclear antibodies"

allows for the detection of the presence of antibodies to glutamic acid decarboxylase

The Anti-C1Q Ab, IgG (RDL) test measures the levels of IgG antibodies against C1q in a patient's blood. What is C1q? C1q is a protein that plays a crucial role in the complement system, which is a part of the immune system responsible for recognizing and clearing pathogens and damaged cells from the body. Patients with suspected autoimmune conditions, particularly lupus nephritis, may undergo this test as part of their diagnostic workup. Systemic lupus erythematosus (SLE) is an autoimmune disease with multiorgan involvement. Approximately 37-45% of patients with SLE will develop lupus nephritis, which negatively impacts patient survival. Testing for C1q antibodies assists in evaluating the risk of lupus nephritis development. Limitations: - Not all patients with lupus nephritis will be positive for C1q antibodies - The presence of C1q antibodies is not specific for SLE

primarily associated with lupus

can confirm the diagnosis of systemic lupus erythematosus

The Anti-dsDNA antibody test, particularly the Farr assay, is a highly specific diagnostic tool pivotal in the evaluation and management of systemic lupus erythematosus (SLE), a complex autoimmune disorder. Double-stranded DNA (dsDNA) antibodies are a type of antinuclear antibody (ANA) that specifically target the DNA within the cell nucleus. These antibodies are considered one of the hallmark indicators of SLE, with their presence being a key criterion in the diagnosis of the disease. The Farr assay, a radioimmunoassay, is renowned for its high specificity in detecting anti-dsDNA antibodies. This assay utilizes radiolabeled DNA to capture antibodies from a patient's serum. The bound antibodies are then measured, providing a quantitative assessment of the anti-dsDNA antibodies present. A positive Farr assay is strongly indicative of SLE, as these antibodies are rarely found in healthy individuals or those with other autoimmune disorders. The presence and levels of anti-dsDNA antibodies, as determined by the Farr assay, are not only critical in confirming a diagnosis of SLE but also invaluable in monitoring the disease's activity and severity. Fluctuations in the levels of these antibodies often correlate with disease flare-ups and remissions, making them a useful marker in assessing response to treatment and guiding clinical decision-making. For patients suspected of having SLE, or for those managing the condition, the Anti-dsDNA antibody test via the Farr assay is a crucial component of the diagnostic and monitoring process. It provides clarity in distinguishing SLE from other autoimmune conditions and helps in tailoring individualized treatment plans.

What is Anti-Fodrin Ab, IgA (RDL)? Anti-Fodrin Antibody, IgA is a blood test that detects IgA-class autoantibodies targeting fodrin, a protein found inside the cells of the salivary and tear glands. These autoantibodies are part of an immune response that mistakenly attacks the body's own moisture-producing tissues—especially in Sjögren’s syndrome. Unlike IgG antibodies, which are more systemic, IgA antibodies are often involved in mucosal and glandular immune responses. Measuring Anti-Fodrin IgA can provide valuable insight into localized glandular autoimmunity—particularly in the early or seronegative stages of disease. Why is this test important? This test is most commonly ordered to help diagnose: Sjögren’s syndrome, especially in patients with chronic dry mouth, dry eyes, or salivary gland swelling Seronegative cases, where common markers like Anti-SSA (Ro) and Anti-SSB (La) are negative Early autoimmune gland involvement before full-blown disease develops What does a positive Anti-Fodrin IgA result mean? A positive Anti-Fodrin Ab, IgA result may indicate: Immune system activity against salivary or lacrimal glands, supporting a diagnosis of Sjögren’s syndrome Possible early-stage or localized autoimmune disease involving mucosal tissues Glandular involvement in other autoimmune conditions, such as lupus or autoimmune thyroid disease This marker is not exclusive to Sjögren’s but is considered helpful when used in combination with symptoms and other test results. What does a negative result mean? A negative Anti-Fodrin IgA result suggests that your immune system is not currently producing detectable IgA antibodies against fodrin. However, this does not rule out Sjögren’s or other autoimmune diseases—other markers or gland biopsies may still be needed, especially if symptoms persist. What happens next if elevated? If your Anti-Fodrin Ab, IgA level is elevated: Your provider may evaluate other markers (e.g., Anti-SSA, ANA, ESR/CRP) and clinical symptoms You might be referred to a rheumatologist for further diagnosis and care Management may involve symptom control (e.g., artificial tears, saliva stimulants), anti-inflammatory treatment, and monitoring for systemic involvement Bottom Line Anti-Fodrin Ab, IgA (RDL) is a useful autoimmune marker for identifying immune system activity targeting glandular tissues, particularly in suspected Sjögren’s syndrome. It may be especially helpful in early-stage or seronegative cases, providing another diagnostic tool when traditional markers are absent. If you’re experiencing symptoms like dry mouth, dry eyes, or salivary gland swelling, this test can offer important insight.

What is Anti-Fodrin Ab, IgG (RDL)? Anti-Fodrin Antibody, IgG is a blood test that looks for autoantibodies targeting a protein called fodrin, which is part of the structural framework (cytoskeleton) inside certain cells—especially those in salivary and tear glands. When the immune system mistakenly attacks fodrin, it can lead to glandular inflammation and dysfunction, contributing to autoimmune conditions. This marker is often used to help diagnose Sjögren’s syndrome, a chronic autoimmune disorder that causes dry mouth, dry eyes, and sometimes systemic symptoms like joint pain and fatigue. What does a positive result mean? A positive Anti-Fodrin Ab, IgG test indicates the presence of immune activity against glandular tissues. This supports a possible diagnosis of: Sjögren’s syndrome, especially in early or “seronegative” cases Other autoimmune diseases like lupus or rheumatoid arthritis with gland involvement This marker is especially useful when classic Sjögren’s antibodies like Anti-SSA (Ro) or Anti-SSB (La) are negative but symptoms still point toward autoimmune glandular disease. What does a negative result mean? A negative result means no detectable anti-fodrin IgG antibodies were found. This doesn’t completely rule out Sjögren’s or other autoimmune conditions—your doctor will consider your symptoms and may order further tests or imaging. Next steps if elevated If your result is positive: Your provider may refer you to a rheumatologist for further evaluation Additional tests (ANA, SSA/SSB, RF, CRP/ESR) may be ordered Management may include tear and saliva substitutes, immunomodulatory therapy, and regular monitoring for complications Bottom Line Anti-Fodrin Ab, IgG (RDL) is a valuable marker for detecting autoimmune activity affecting the body’s moisture-producing glands. It plays a key role in supporting the diagnosis of Sjögren’s syndrome, especially when other antibodies are negative but symptoms persist. Early detection can lead to better symptom control and monitoring for related autoimmune conditions.

Autoimmune nuclear antibodies

measures specific antibodies in your blood that target Immunoglobulin E

Key biomarker for autoimmune disease diagnosis

An indicator for Lupus

related to A Streptococcus infection

produced by immune system against platelet membrane phospholipids

produced by immune system against platelet membrane phospholipids

produced by immune system against platelet membrane phospholipids

commonly used to help diagnose autoimmune conditions

Antinuclear Antibodies (ANA) are a group of autoantibodies that target substances found in the nucleus of a cell. The ANA screen is a preliminary test used to detect the presence of these antibodies in the blood, which may indicate the presence of an autoimmune disorder. When an ANA screen yields a positive or indeterminate result, a Reflex ANA IFA (Indirect Fluorescent Antibody) test may be performed for a more detailed analysis. This test can identify specific patterns of fluorescence that correlate with various types of autoimmune diseases. Additionally, the detection of double-stranded DNA (dsDNA) antibodies, through a reflex test, is especially significant as these are highly specific for systemic lupus erythematosus (SLE), a chronic autoimmune disease. The presence of dsDNA antibodies can be indicative of the disease activity and severity. Therefore, the combination of these tests aids clinicians in diagnosing, monitoring, and managing autoimmune conditions, although the results are always considered in the broader context of clinical symptoms and other diagnostic findings.

Autoantibodies

aid in the diagnosis of certain autoimmune thrombotic disorders

aid in the diagnosis of certain autoimmune thrombotic disorders

aid in the diagnosis of certain autoimmune thrombotic disorders

to help determine a recent strep infection with group A Streptococcus:

Associated with inappropriate blood clotting

The antiphospholipid antibody syndrome (APS) is a clinical-pathologic correlation that includes a clinical event (e.g. thrombosis, pregnancy loss, thrombocytopenia) and persistent positive antiphospholipid antibodies (IgM or IgG ACA >40 MPL/GPL,IgM or IgG anti-b2GPI antibodies or a lupus anticoagulant). International consensus guidelines for APS suggest waiting at least 12 weeks before retesting to confirm antibody persistence. The Systemic Lupus International Collaborating Clinics immunological classification criteria for systemic lupus erythematosus (SLE) include testing for isotype IgA, which has yet to be incorporated into APS criteria. Low level antiphospholipid antibodies may sometimes be detected in the setting of infection, drug therapy or aging.

contributes to the diagnosis of APS

The Beta Strep Gp A Culture test is used to detect the presence of Group A Streptococcus (GAS) bacteria, also known as Streptococcus pyogenes. This bacterium is a common cause of strep throat, skin infections, and in some cases, more serious illnesses like scarlet fever, rheumatic fever, or invasive streptococcal disease. Why the Test Is Done This culture is typically ordered when a person has symptoms such as: Sore throat with fever Red, swollen tonsils (possibly with white patches) Difficulty swallowing Swollen lymph nodes in the neck Skin infections or impetigo In children and adults, the test helps differentiate between viral and bacterial throat infections. Since antibiotics are only effective against bacteria, it's crucial to confirm a Group A Strep infection before starting treatment. How the Test Works A healthcare provider collects a sample by swabbing the throat or affected skin area. The sample is then cultured (grown) in a lab to see if Group A Streptococcus is present. Positive Result: Indicates an active infection with Group A Strep bacteria. Antibiotic treatment may be recommended. Negative Result: No Group A Strep was found in the sample. Symptoms may be due to a viral infection or another cause. What It Means for You A positive culture confirms the need for antibiotics to reduce the duration of symptoms, prevent complications, and reduce transmission. If you're experiencing symptoms and receive a negative result, your doctor might look into other causes or recommend additional testing. Summary The Beta Strep Gp A Culture is a reliable diagnostic tool for identifying Group A Streptococcus infections. Understanding your results can help guide timely treatment and prevent complications.

Bordetella pertussis is the bacterium responsible for causing whooping cough, a highly contagious respiratory illness. The Bordetella pertussis toxin (PT) IgG antibody test is an immunoassay (IA) designed to detect the presence of IgG antibodies against the pertussis toxin. These antibodies are produced by the immune system in response to an infection with Bordetella pertussis or, in some cases, following vaccination. The presence of IgG antibodies to the pertussis toxin can indicate either a past infection with Bordetella pertussis or a response to a recent vaccination, as the pertussis vaccine (DTP or DTaP) contains inactivated components of the toxin. This marker is particularly useful for diagnosing recent or past infections, as well as for assessing immunity in individuals who may have been vaccinated or exposed to the bacteria. In general, high levels of IgG antibodies to the pertussis toxin suggest that a person has either been exposed to the bacterium or vaccinated, and may indicate immunity against future infections. However, a positive result alone cannot confirm whether the antibodies are a result of a current infection or past exposure, as the body may continue to produce IgG antibodies for years after the initial exposure. The Bordetella pertussis toxin (PT) IgG antibody test is commonly used in conjunction with other diagnostic tests, such as PCR (Polymerase Chain Reaction) or culture tests, to confirm a diagnosis of pertussis, particularly in individuals who present with symptoms resembling those of the disease but may not have the characteristic "whooping" cough. This test plays a crucial role in public health surveillance, especially in monitoring pertussis outbreaks and assessing vaccination coverage in populations. It also provides valuable insight for healthcare providers in diagnosing and managing whooping cough in individuals who may have had previous exposures or vaccinations.

C1 Esterase Inh. Ag (Antigen) – What Your Lab Test Means What is C1 Esterase Inhibitor Antigen (C1-INH Ag)? C1 Esterase Inhibitor Antigen, often abbreviated as C1-INH Ag, is a blood test that measures the amount of C1 esterase inhibitor protein in your blood. This protein plays a crucial role in regulating parts of your immune system and the complement system, which helps fight infections and control inflammation. Why is this marker important? C1 esterase inhibitor helps keep your immune system in balance by preventing excessive activation of the complement pathway, a part of your immune defense. If you don’t have enough of this protein, or if it’s not working properly, it can lead to uncontrolled inflammation and swelling in the body. What does this test diagnose? This test is most commonly used to help diagnose Hereditary Angioedema (HAE) Type I — a rare but serious genetic condition that causes sudden, recurrent episodes of swelling in the face, throat, abdomen, limbs, or airway. It may also be used to evaluate: Acquired angioedema (AAE), which can occur in adults due to other conditions like lymphomas or autoimmune disorders. Unexplained recurrent swelling or abdominal pain without allergic triggers. What do the results mean? C1-INH Antigen Level Possible Interpretation Low Suggests Type I Hereditary Angioedema (HAE) or Acquired Angioedema (AAE) Normal or High If symptoms persist, a functional C1-INH test may be needed to check whether the protein is working properly (to rule out Type II HAE) It’s important to interpret this result alongside C4 levels and possibly a C1-INH functional assay for a full diagnostic picture. Symptoms that may prompt this test Swelling of the face, lips, tongue, throat, or extremities Abdominal pain, cramping, or bloating Difficulty breathing during swelling episodes No response to standard allergy medications (like antihistamines or steroids) How is the test performed? A blood sample is drawn, usually from a vein in your arm. No special preparation is needed in most cases. Related Tests Doctors often order additional tests alongside C1-INH Ag for a more complete diagnosis: C1 Esterase Inhibitor, Functional – Measures whether the protein works properly Complement C4 levels – Often low during HAE attacks C1q level – May help differentiate hereditary vs. acquired angioedema Bottom Line The C1 Esterase Inh. Ag (Antigen) test measures how much of this critical immune-regulating protein is in your blood. A low result can point to Type I Hereditary Angioedema, a condition that causes episodes of swelling that can be life-threatening if untreated. If your antigen level is normal but symptoms continue, your doctor may order further tests to check how well the protein is functioning.

Diagnosing hereditary angioedema, monitoring response to C1 esterase inhibitor replacement therapy

Measurement of the C1 esterase inhibitor (the first component of the complement) is used to diagnose hereditary angioedema and to monitor levels of the inhibitor during treatment. What is hereditary angioedema? Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (= angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack. Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty. On average, untreated individuals have an attack every 1 to 2 weeks, and most episodes last for about 3 to 4 days. The frequency and duration of attacks vary greatly among people with hereditary angioedema, even among people in the same family. There are three types of hereditary angioedema, called types I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The different types have similar signs and symptoms. Type III was originally thought to occur only in women, but families with affected males have been identified. The most common form (85% of cases) of hereditary angioedema is due to an absolute decrease in the amount of C1 esterase inhibitor. A less common form (15% of cases) is due to the functional abnormality of the inhibitor where levels may be normal. Both abnormalities need to be tested because of the potentially life-threatening nature of the disease. In addition to the decreased serum esterase C1 inhibitor in patients with hereditary angioedema, there is still a unique quinine polypeptide at elevated concentration during the edema crisis. Patients with episodes of hereditary angioedema also have a low total complement and C4 and C2 components of the complement. Hereditary angioedema is transmitted in an autosomal dominant manner. Heterozygotes also have reduced levels of the C1 esterase inhibitor. During acute attacks of the disease, complement components of C4 and C2 may be significantly reduced, but C1 and C3 components are normal. The factors that promote the onset of angioedema attacks are often unknown. Notes: - Angioedema can also occur as an acquired disease. The acquired form includes non-hereditary C1 esterase deficiency and may be caused by medications, allergies, idiopathic forms, angioedema associated with autoimmune disease especially with systemic lupus erythematosus and hypereosinophilia, angioedema occasionally associated with malignancy, and angioedema caused by natural stimuli. - Abnormally low results are consistent with a heterozygous C1 esterase inhibitor deficiency and hereditary angioedema. - Fifteen percent of hereditary angioedema patients have a normal or elevated level but nonfunctional C1 esterase inhibitor protein. Detection of these patients requires a functional measurement of C1 esterase inhibitor; FC1EQ / C1 Esterase Inhibitor, Functional Assay, Serum. - Measurement of C1q antigen levels; C1Q / Complement C1q, Serum, is key to the differential diagnoses of acquired or hereditary angioedema. Those patients with the hereditary form of the disease will have normal levels of C1q, while those with the acquired form of the disease will have low levels. - Studies in children show that adult levels of C1 inhibitor are reached by 6 months of age. References: Atkinson JP, Du Clos TW, Mold C, Kulkarni H, Hourcade D, Wu X. The human complement system: basic concepts and clinical relevance. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, eds. Clinical Immunology: Principles and Practice. 5th ed. Philadelphia, PA: Elsevier; 2019:chap 21. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616. PMID: 24673465 www.ncbi.nlm.nih.gov/pubmed/24673465/. Leslie TA, Greaves MW. Hereditary angioedema. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson IH, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 5th ed. Philadelphia, PA: Elsevier; 2018:chap 101. Zanichelli A, Azin GM, Wu MA, et al. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2017;5(5):1307-1313. PMID: 28284781 www.ncbi.nlm.nih.gov/pubmed/28284781/. Frank MM: Complement deficiencies. Pediatr Clin North Am. 2000;47(6):1339-1354 Gelfand JA, Boss GR, Conley CL, et al: Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine. 1979;58(4):321-328 Rosen FS, Alper CA, Pensky J, et al: Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest. 1971;50(10):2143-2149 Frigas E: Angioedema with acquired deficiency of the C1 inhibitor: a constellation of syndromes. Mayo Clin Proc. 1989;64:1269-1275 Soldin SJ, Hicks JM, Bailey J, et al: Pediatric reference ranges for estradiol and C1 esterase inhibitor. Clin Chem. 1998;44(6s):A17

desArg = without arginine

Immune complex activation marker

A complement protein fragment, important in immune response and inflammation.

produced by immune system against platelet membrane phospholipids

Measures serum IgG antibodies to cardiolipin for APS evaluation.

IgM antibodies targeting cardiolipin phospholipids; marker for APS.

Carnitine, Esters: Explanation of the Biomarker in a Carnitine and Acylcarnitine Panel Carnitine esters are a group of compounds formed when carnitine binds to fatty acids. These esters play a critical role in the transport of long-chain fatty acids into the mitochondria, where they are used for energy production. This process is essential for cellular metabolism, particularly in tissues with high energy demands, such as muscles and the heart. In a Carnitine and Acylcarnitine panel, the measurement of carnitine esters (expressed in µmol/L) provides valuable insight into the body's ability to metabolize fatty acids and produce energy efficiently. Elevated or decreased levels of carnitine esters can indicate underlying metabolic or mitochondrial disorders, and abnormalities may suggest issues with fatty acid metabolism, such as primary carnitine deficiency or other metabolic conditions. Reference Range Normal Range: 4-13 µmol/L Interpretation: Values outside the reference range may indicate metabolic irregularities. Lower levels could suggest impaired fatty acid transport or mitochondrial dysfunction, while higher levels might be linked to conditions affecting fatty acid metabolism or a disturbance in carnitine uptake. Clinical Relevance: Low Levels: Carnitine ester deficiency can result from genetic disorders like primary carnitine deficiency or secondary deficiencies due to poor dietary intake, certain medications, or malabsorption conditions. This can lead to muscle weakness, fatigue, and in severe cases, heart and liver issues. High Levels: Elevated carnitine esters might indicate conditions such as disorders of fatty acid oxidation or an excess of free carnitine in the system. It may also be observed in cases of kidney dysfunction, where carnitine is not properly metabolized or excreted. Measuring carnitine esters alongside other biomarkers in the panel can help clinicians diagnose metabolic disorders and tailor appropriate treatments to manage any identified conditions. If you notice abnormal results for carnitine esters, consulting with a healthcare provider is crucial for further investigation and management.

Rheumatoid arthritis test

directed against centromere proteins.

a Marker Detection of Lupus Nephropathy

detect antibodies in response to Coccidioides immitis/posadasii

detects IgG antibodies against the fungus Coccidioides immitis

Coccidioides Ab, IgM, EIA refers to a laboratory test that detects IgM antibodies against the fungus Coccidioides immitis, which causes coccidioidomycosis, also known as Valley Fever. This test is used to diagnose and monitor infections caused by this fungus. IgM antibodies are produced as a body’s first response to a new infection or to a new “non-self” antigen, providing short-term protection. They increase for several weeks and then decline as IgG production begins. Valley fever, also called coccidioidomycosis, is an infection caused by the fungus Coccidioides. The fungus is known to live in the soil in the southwestern United States and parts of Mexico and Central and South America. The fungus was also recently found in south-central Washington. People can get Valley fever by breathing in the microscopic fungal spores from the air, although most people who breathe in the spores don’t get sick. Usually, people who get sick with Valley fever will get better on their own within weeks to months, but some people will need antifungal medication. Certain groups of people are at higher risk for becoming severely ill. It’s difficult to prevent exposure to Coccidioides in areas where it’s common in the environment, but people who are at higher risk for severe Valley fever should try to avoid breathing in large amounts of dust if they’re in these areas. Results are reported in EIA (Enzyme Immunoassay) units. A positive result indicates the presence of IgM antibodies in response to Coccidioides infection, while a negative result suggests their absence. The level of antibodies can help assess the stage of infection. Different laboratories may have specific cutoff values for positivity.

Investigation of renal/joint/connective tissue disorders and their symptoms.

A pro-inflammatory mediator

C4 is the most second-most abundant of the 11 complement proteins (after C3)

associated with inflammation

Complement Component C1Q is a vital element in the field of immunology and diagnostic medicine, playing a crucial role in the assessment of autoimmune and inflammatory disorders. This component forms part of the complement system, a group of proteins that enhance (complement) the ability of antibodies and phagocytic cells to clear pathogens from an organism. C1Q specifically initiates the classical complement pathway, a critical part of the body's innate immune response. Testing for Complement Component C1Q levels is particularly significant in diagnosing conditions such as Systemic Lupus Erythematosus (SLE) and other rheumatic diseases. In SLE, low levels of C1Q can be indicative of active disease and are often associated with lupus nephritis, a serious kidney complication. The test for C1Q is also useful in identifying C1Q deficiency, a rare genetic condition that significantly increases the risk of developing SLE. Furthermore, monitoring C1Q levels can assist in the management of immune-complex-mediated conditions, where the activation of the complement system plays a pathogenic role. The assessment of Complement Component C1Q underscores the importance of detailed immunological evaluations in providing accurate diagnoses and effective management plans for patients with autoimmune disorders.

Serum immune test measuring total complement system activity level.

Complement was discovered by Jules Bordet as a heat-labile component of normal plasma that causes the opsonisation and killing of bacteria. The complement system refers to a series of >20 proteins, circulating in the blood and tissue fluids. Most of the proteins are normally inactive, but in response to the recognition of molecular components of microorganisms they become sequentially activated in an enzyme cascade – the activation of one protein enzymatically cleaves and activates the next protein in the cascade. The complement system plays a critical role in inflammation and defence against some bacterial infections. Complement may also be activated during reactions against incompatible blood transfusions, and during the damaging immune responses that accompany autoimmune disease. Deficiencies of individual complement components or inhibitors of the system can lead to a variety of diseases, which gives some indication of their role in protection against disease. The Complement Total, or CH50 Blood Test, assesses the overall activity of the complement system, and mainly evaluates the classic complement activation pathway. A CH50 Blood Test is often ordered to evaluate complement component deficiency and evaluate complement activity in cases of immune complex disease, glomerulonephritis (inflammation of the kidneys filters), rheumatoid arthritis and cryoglobulinemia (abnormal proteins in the blood that thicken in cold temperatures). It can also be used to evaluate a persons response to systemic lupus erythematosus (SLE) therapy and predict disease flares. This test is usually ordered for people with a family history of complement deficiency and those who have symptoms of: - RA - kidney disease - lupus, which is a multisystem autoimmune disease - myasthenia gravis - an infectious disease, such as meningitis - cryoglobulinemia, which is the presence of abnormal proteins in the blood

To help diagnose rheumatoid arthritis (RA) and differentiate it from other types of arthritis.

The marker Cysticercosis (Taenia solium) refers to a diagnostic test used to detect the presence of antibodies against Taenia solium, the parasitic tapeworm responsible for cysticercosis. Cysticercosis is an infection that occurs when a person ingests eggs from the tapeworm, which are typically spread through contaminated food, water, or contact with infected feces. Once inside the body, the eggs hatch into larvae and can migrate to various tissues, including muscles, eyes, and the central nervous system, forming cysts. This can lead to a range of symptoms, depending on the location and number of cysts. For example, if cysts form in the brain, a condition known as neurocysticercosis, it can cause seizures, headaches, and other neurological issues. The test checks for antibodies in the blood, indicating that the immune system has responded to a Taenia solium infection. A positive result suggests either a current or past infection. This test is crucial for diagnosing cysticercosis, particularly in individuals who exhibit symptoms suggestive of the disease or who have a history of exposure to regions where the tapeworm is common. Proper diagnosis is essential for effective treatment and management of the infection, which may include antiparasitic medications, anti-inflammatory drugs, and sometimes surgery to remove cysts.

Detection of lupus anticoagulant

Diphtheria antitoxoid antibodies are specific immunoglobulins (also known as antibodies) produced by the human immune system in response to the diphtheria toxoid vaccine or exposure to the bacterium Corynebacterium diphtheriae, which causes diphtheria. What is Diphtheria? Diphtheria is a serious bacterial infection that can lead to difficulty breathing, heart rhythm problems, and even death. It's caused by strains of bacteria called Corynebacterium diphtheriae that make toxin. Diphtheria spreads easily and happens quickly, and mainly affects the nose and throat. It's spread from person to person, usually through respiratory droplets, from coughing or sneezing. These antibodies play a crucial role in conferring immunity against the potentially fatal diphtheria toxin. The presence and level of these antibodies in the blood are indicative of an individual's immune status to diphtheria; a higher titer of antitoxoid antibodies typically suggests adequate protective immunity. The diphtheria vaccine, which is part of routine childhood immunization programs worldwide, contains a modified form of the toxin (toxoid) to safely stimulate the production of antitoxoid antibodies without causing disease. Monitoring levels of diphtheria antitoxoid antibodies can help determine the need for booster vaccinations to maintain immunity and prevent outbreaks of this serious infectious disease.

a diagnostic criterion of systemic lupus erythematosus (SLE)

The DNA AB Double Stranded (dsDNA) titer is a laboratory test used to detect the presence of autoantibodies against double-stranded DNA in the blood. These autoantibodies are often associated with autoimmune diseases, most notably Systemic Lupus Erythematosus (SLE). A positive titer is considered a hallmark for the diagnosis of SLE and can correlate with disease activity, especially in relation to lupus nephritis or kidney involvement. While strongly linked with SLE, anti-dsDNA antibodies can occasionally appear in other autoimmune conditions. Interpretation of the test result should always be in the context of clinical symptoms, other laboratory findings, and the expertise of a rheumatologist or relevant specialist.

Useful to evaluate patients with signs and symptoms consistent with lupus erythematosus (SLE). Of the systemic lupus erythematosus (SLE)-specific antibodies the antibodies to double-stranded DNA (dsDNA) is the most common. Testing for IgG antibodies to dsDNA is indicated in patients positive for anti-cellular antibody (ie, antinuclear antibody: ANA) homogeneous pattern using HEp-2 substrate by indirect immunofluorescence assay (IFA) along with clinical features compatible with SLE. A minority of SLE patients may test negative using HEp-2 by IFA for nuclear antibodies. Testing antibodies associated with HEp-2 IFA cytoplasmic pattern such as ribosomal P IgG autoantibodies may be useful if features of neuropsychiatric disease are present. Alternatively, patients may be tested for Smith, ribonucleoprotein, SSA-52, and SSA-60 antibodies. The levels of antibodies to dsDNA may fluctuate with SLE disease activity. Increasing antibody levels may be associated with flares while decline or negative results may indicate response to treatment or disease remission.

measures the presence of lupus anticoagulants

Detection of lupus anticoagulant

The dRVVT Screen Ratio is a key component of lupus anticoagulant (LA) testing. It is calculated from the dilute Russell's viper venom time (dRVVT) screen test, which uses a low-phospholipid reagent to increase sensitivity to lupus anticoagulant. A normal dRVVT screen ratio is typically less than 1.20, while an elevated ratio (≥1.20) may suggest the presence of LA. However, elevated results can also arise from coagulation factor deficiencies, anticoagulant medications, or other inhibitors. The screen ratio is determined by dividing the patient’s plasma clotting time by the clotting time of normal pooled plasma. When the ratio is elevated, additional tests, such as mixing studies and confirmatory assays, are often performed to distinguish lupus anticoagulant from other causes of prolonged clotting times. The dRVVT screen ratio is frequently used in combination with other tests, such as aPTT, as part of a comprehensive lupus anticoagulant panel. When incorporated into a reflexive testing algorithm, it has a sensitivity of approximately 65-70% for diagnosing lupus anticoagulant. This multi-step approach enhances diagnostic accuracy, particularly when interpreting complex coagulation abnormalities.

Evaluating patients with signs and symptoms consistent with systemic lupus erythematosus (SLE).

double stranded DNA

The marker ECP on a LabCorp panel refers to Eosinophil Cationic Protein, a protein released by activated eosinophils—white blood cells involved in the body's immune response, particularly in allergic reactions and parasitic infections. ECP plays roles in immune regulation and has cytotoxic and neurotoxic properties. Clinical Significance Measuring ECP levels in the blood can provide insights into eosinophil activity and is useful in evaluating and monitoring various conditions, including: Asthma: Elevated ECP levels can reflect the degree of eosinophilic inflammation in the airways, aiding in assessing asthma severity and guiding corticosteroid therapy. Allergic Conditions: In diseases like allergic rhinitis and atopic dermatitis, increased ECP levels correlate with symptom severity, making it a valuable marker for disease activity. Eosinophilic Gastrointestinal Disorders: Conditions such as eosinophilic esophagitis, gastroenteritis, and colitis may show elevated ECP levels, reflecting eosinophil-mediated inflammation. Parasitic Infections: ECP levels can rise in response to certain parasitic infestations, indicating an active eosinophilic response. Hypereosinophilic Syndromes: In disorders characterized by persistently high eosinophil counts, ECP measurement can help assess disease activity and organ involvement.

Extractable Nuclear Antigen (ENA) Screen

The ENA (Extractable Nuclear Antigens) to Smith (Sm) antibody test plays a pivotal role in the field of autoimmune diagnostics, particularly in the context of systemic lupus erythematosus (SLE). Smith antibodies are a subset of antinuclear antibodies (ANAs), specifically targeting proteins found within the cell nucleus, known as Sm antigens. These antigens are integral to the splicing of pre-mRNA, making them vital for cell function. In autoimmune conditions like SLE, the body's immune system mistakenly targets its own tissues, with Smith antibodies being one of the markers of this aberrant immune response. The presence of Smith antibodies is considered highly specific for SLE; while they are not found in all patients with SLE, their presence is rarely observed in other diseases. This specificity makes the ENA to Sm antibody test an invaluable tool in the differential diagnosis of SLE, distinguishing it from other autoimmune disorders that may present with similar symptoms. Testing for Smith antibodies is typically conducted through blood serum analysis using techniques like enzyme-linked immunosorbent assay (ELISA) or immunofluorescence. A positive test result for Smith antibodies, especially when correlated with clinical symptoms and other laboratory findings, can significantly aid in the diagnosis of SLE. Moreover, monitoring the levels of these antibodies can provide insights into the disease's progression and response to treatment. Understanding the significance of ENA to Smith antibodies in SLE is essential for both patients and healthcare professionals. It guides diagnosis, informs treatment strategies, and enhances the understanding of the disease process. For individuals undergoing evaluation for autoimmune disorders, especially those with symptoms suggestive of SLE, discussing the possibility of Smith antibody testing with a healthcare provider can be a critical step in their diagnostic journey.

The ENA-6 Reflexed test is a blood test used to help diagnose autoimmune diseases, particularly those that affect the connective tissues, such as Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, scleroderma, and polymyositis. "ENA" stands for Extractable Nuclear Antigens, which are proteins found inside the nucleus of cells that can become targets of the immune system in autoimmune diseases. The "6" refers to six specific antigens included in this panel: SS-A (Ro), SS-B (La), Sm, RNP, Scl-70, and Jo-1. Each of these antigens is associated with different autoimmune conditions, and identifying antibodies against them can provide valuable clues for diagnosis. For example, antibodies against SS-A and SS-B are often found in patients with Sjögren's syndrome, while antibodies against Sm are highly specific for SLE. When a doctor orders an ENA-6 Reflexed test, they are looking to see if a patient’s immune system is producing antibodies against any of these six antigens. If the initial screening test (typically an antinuclear antibody, or ANA test) comes back positive, the ENA-6 test is automatically "reflexed" or performed next to further pinpoint which specific antibodies are present. This step-by-step approach helps doctors narrow down the possible autoimmune diseases a patient might have. By understanding which antibodies are present, doctors can tailor treatment plans more effectively and monitor disease progression more accurately. In summary, the ENA-6 Reflexed test is a critical tool in the diagnosis and management of various autoimmune diseases, providing specific information that helps guide patient care.

associated with the body's immune response mechanisms

An ESR test can help determine if you have a condition that causes inflammation.

a valuable indicator of carnitine metabolism

IgE-mediated wheat allergy is a gluten-related disorder.

Light chains are proteins produced by immune cells called plasma cells. Also called kappa light chains, they link together with other proteins (heavy chains) to form immunoglobulins (= antibodies) that target and neutralize specific threats to the body (= bacteria & viruses). Plasma cells normally produce some excess light chains that do not combine with heavy chains and instead enter the bloodstream. Free light chains refer to those that are not part of whole (= intact) immunoglobulins and are present in the blood. This test measures the amount of free kappa and light chains in the blood to help detect, diagnose, and monitor conditions associated with an increased production of free light chains. Each type of immunoglobulin is composed of four protein chains: 2 identical heavy chains and 2 identical light chains. A particular plasma cell will produce only one type of immunoglobulin. Normally, there is a slight excess of free light chains produced, so low levels of free kappa and lambda chains are detected in the blood. References: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629951/ https://labtestsonline.org/tests/serum-free-light-chains

Free Light Chains, Type Lambda (Serum) measures the amount of unbound lambda light chains circulating in the bloodstream. Light chains are components of immunoglobulins (antibodies) produced by plasma cells, and they exist in two types — kappa and lambda. Normally, small amounts of free light chains are present in the blood, but elevated levels of lambda free light chains may indicate an abnormal plasma cell proliferation, such as multiple myeloma, AL amyloidosis, or monoclonal gammopathy of undetermined significance (MGUS). When interpreted together with free kappa light chains and the kappa/lambda ratio, this test helps distinguish between polyclonal (nonspecific immune activation) and monoclonal (clonal plasma cell disorder) patterns. A normal or low lambda concentration generally suggests the absence of a monoclonal process, though results should always be interpreted alongside other laboratory data and clinical findings.

The Fusarium Proliferatum/Moniliforme IgG test measures levels of IgG antibodies in your blood that are specific to Fusarium proliferatum and Fusarium moniliforme—two types of environmental molds (fungi) often found in soil, water-damaged buildings, and decaying plant material. Why It Matters: This test is typically ordered to assess immune system exposure to these molds—not to diagnose an active infection or allergy. Elevated IgG levels suggest prior or ongoing exposure, but they do not confirm disease or mold-related illness by themselves. Fusarium species can sometimes be associated with: Chronic respiratory symptoms Hypersensitivity pneumonitis Environmental mold exposure syndromes However, the presence of IgG antibodies only tells us that your immune system has recognized and responded to the mold—not whether that response is causing symptoms or illness. Important Limitations: Elevated IgG does not necessarily mean you have a current infection or disease. It is not used to diagnose mold toxicity or acute mold allergies. The test is best interpreted by specialists who understand the clinical context, such as infectious disease physicians or allergists. Reference ranges are based on people without unusual mold exposure and carry no direct disease significance. When Is This Test Helpful? This test may be considered when: You have ongoing respiratory issues with suspected environmental causes There’s a history of significant mold exposure (e.g., living in a water-damaged building) You're being evaluated for hypersensitivity pneumonitis or chronic mold-related conditions Next Steps: If you’ve had this test done and are unsure what the results mean, consult your healthcare provider—especially if you have unexplained respiratory symptoms or known mold exposure.

Gammaglobulin A refers to the portion of the gamma globulin protein fraction that includes Immunoglobulin A (IgA), a key antibody involved in immune defense. IgA is primarily found in mucosal areas such as the respiratory and gastrointestinal tracts, as well as in secretions like saliva, tears, and breast milk. It plays a crucial role in neutralizing pathogens at mucosal surfaces, helping prevent infections before they enter the bloodstream. While the term "gammaglobulin A" is sometimes used interchangeably with IgA, it more broadly reflects the presence of IgA within the gamma globulin class of serum proteins. Abnormal levels of gammaglobulin A—or more specifically, IgA—may indicate immune disorders, chronic infections, or certain inflammatory conditions.

Gamma globulin G, more precisely known as Immunoglobulin G (IgG), is the most abundant type of antibody in the human body, accounting for approximately 75% of all serum immunoglobulins. As a key component of the gamma globulin fraction of blood proteins, IgG plays a critical role in the immune system's defense against bacterial and viral infections. It is produced by plasma cells and circulates in the blood and extracellular fluid, where it recognizes and binds to specific antigens, marking them for destruction by other immune cells. IgG is also the only antibody class that can cross the placenta, providing passive immunity to newborns. Clinically, IgG levels are often measured to assess immune function or to diagnose conditions such as immunodeficiencies, chronic infections, or autoimmune diseases.

Gamma globulin M, more accurately referred to as immunoglobulin M (IgM), is the first type of antibody produced by the immune system in response to an infection. It is a part of the gamma globulin fraction of serum proteins and plays a critical role in the body’s initial defense against pathogens. IgM is primarily found in the blood and lymphatic fluid, and because of its large size, it is especially effective at forming complexes with antigens and activating the complement system. Elevated levels of IgM can indicate recent or acute infections, autoimmune disorders, or certain types of blood cancers, while low levels may suggest immune deficiencies. As the immune response progresses, IgM is typically replaced by other immunoglobulins such as IgG, which provide longer-lasting immunity.

Understanding Ganglioside Antibodies - GM1 (IgG) If you’ve come across Ganglioside Antibodies - GM1 (IgG) on your lab report, you may wonder what it indicates and why this test was ordered. This biomarker detects IgG antibodies against GM1, a type of ganglioside found in the nervous system. Elevated levels of these antibodies can provide important clues about certain neurological conditions. What Are Ganglioside Antibodies? Gangliosides are complex molecules found in the membranes of nerve cells, where they play critical roles in nerve signaling and function. Sometimes, the immune system mistakenly produces antibodies against these gangliosides, such as GM1, leading to potential damage to the nervous system. GM1 IgG antibodies are specifically associated with certain autoimmune neuropathies. Why Was This Test Ordered? Your healthcare provider may have ordered this test if you are experiencing symptoms such as: Progressive muscle weakness or paralysis. Numbness, tingling, or loss of sensation. Difficulty walking or coordinating movements. Loss of reflexes or other signs of nerve damage. Testing for GM1 (IgG) antibodies helps pinpoint the underlying cause of these symptoms, especially in cases of suspected autoimmune neuropathy.

Understanding Ganglioside Antibodies - GM1 (IgM) If you’ve seen Ganglioside Antibodies - GM1 (IgM) on your lab report, you might have questions about what it means and why it was tested. This biomarker measures the presence of specific IgM antibodies targeting GM1, a type of ganglioside found in the nervous system. Elevated levels of these antibodies can be associated with certain neurological conditions. What Are Ganglioside Antibodies? Gangliosides are complex molecules found on nerve cell surfaces, playing an essential role in nerve function. In some cases, the immune system mistakenly produces antibodies against these gangliosides, including GM1. The presence of GM1 antibodies (specifically IgM) can indicate an autoimmune process targeting the nervous system. Why Was This Test Ordered? Your doctor may have ordered this test if you are experiencing symptoms such as: Progressive muscle weakness. Numbness or tingling in the limbs. Difficulty with coordination or walking. Loss of reflexes. Testing for GM1 antibodies helps identify autoimmune neuropathies and guide treatment decisions. Key Takeaway Whether your result is "Detected" or "Not Detected," it’s important to interpret the findings in the context of your overall health. Ganglioside Antibodies - GM1 (IgM) is just one part of the diagnostic process. Work with your healthcare provider to understand what your test result means and determine the next steps for your care.

Understanding Ganglioside Antibodies - GQ1b (IgG) If you’ve come across Ganglioside Antibodies - GQ1b (IgG) on your lab report, you might be wondering what it means and how it relates to your health. This test measures the presence of specific antibodies in your blood that target a molecule called GQ1b, a type of ganglioside found in the nervous system. What Are Ganglioside Antibodies? Gangliosides are complex lipids that play important roles in the function of nerve cells. In some cases, the immune system mistakenly identifies gangliosides as harmful and produces antibodies against them. These are known as ganglioside antibodies, and their presence can be associated with certain neurological conditions. The GQ1b ganglioside is particularly important because it is found in specific areas of the nervous system, including cranial nerves and the neuromuscular junction. Why Was This Test Ordered? Your healthcare provider may have ordered this test if you are experiencing symptoms like: Muscle weakness or paralysis. Difficulty with eye movements or double vision. Loss of reflexes. Coordination issues. The results can help guide the diagnosis and management of conditions affecting the peripheral nervous system.

a hormone that your stomach makes

a potential marker of systemic inflammation

Haemophilus Influenzae Type B Antibody (IgG): What It Is and Why It Matters Haemophilus influenzae type B (Hib) is a bacterium that can cause serious infections, particularly in young children and individuals with weakened immune systems. These infections include meningitis, pneumonia, epiglottitis, and septicemia. The Hib antibody (IgG) test measures the presence and levels of IgG antibodies against Hib, which are critical for determining immunity to this pathogen. Why Test for Hib IgG Antibodies? Assessing Immunity Hib vaccination is part of routine immunization schedules. The IgG antibody test evaluates whether a person has developed adequate immunity after vaccination. For those who have not been vaccinated, the test can indicate past exposure to the bacterium. Evaluating Immune Response In individuals with suspected immune system disorders, the test helps assess the body's ability to produce an appropriate antibody response to Hib. Diagnosis of Susceptibility Low or absent levels of Hib IgG antibodies suggest vulnerability to Hib infections, prompting the need for vaccination or additional medical intervention. What Do the Results Mean? Elevated Levels: High levels of Hib IgG antibodies usually indicate immunity, either from vaccination or prior infection. Low or Undetectable Levels: Insufficient antibody levels suggest a lack of immunity, increasing the risk of Hib infections. This can occur in individuals who are unvaccinated, under-vaccinated, or have an impaired immune response. Who Should Be Tested? Post-vaccination Monitoring: To confirm the effectiveness of the Hib vaccine, especially in individuals at high risk of infections. Immune Deficiency Evaluation: For those with recurrent infections or suspected immune system disorders, such as primary immunodeficiencies. High-Risk Individuals: Patients undergoing chemotherapy, organ transplantation, or other treatments that suppress the immune system. Importance of Vaccination Vaccination against Hib has significantly reduced the prevalence of severe Hib infections worldwide. However, individuals with low IgG antibody levels remain at risk, making this test essential for targeted prevention and management. Next Steps After Testing If antibody levels are insufficient, your healthcare provider may recommend: Revaccination to boost immunity. Further testing for immune function if an impaired response is suspected. By ensuring adequate protection against Hib, this test plays a critical role in preventing life-threatening infections and supporting overall public health efforts.

The marker Helicobacter pylori Abs, Serum, detected through a serology test using the immunochromatography method, is a crucial diagnostic tool in identifying infections caused by the Helicobacter pylori bacteria. This bacteria is known to cause various gastrointestinal issues, including peptic ulcers and chronic gastritis, and is also associated with an increased risk of stomach cancer. The test works by detecting specific antibodies in the blood that are produced in response to an H. pylori infection. The immunochromatography method is a simple and rapid technique that involves a test strip, which, when exposed to a blood sample, will show visible lines indicating the presence or absence of these antibodies. The process is straightforward and non-invasive, making it a convenient option for both patients and healthcare providers. A positive result indicates that the individual has been exposed to the bacteria and has developed an immune response, while a negative result suggests the absence of an active infection. This test is particularly useful for initial screenings and for confirming suspicions of H. pylori-related gastrointestinal conditions, guiding further diagnostic and treatment decisions. ----------------- Helicobacter pylori Abs, Serum: Understanding a Positive Test Result A positive test result for Helicobacter pylori Abs, Serum indicates that the individual has been exposed to the Helicobacter pylori bacteria and their immune system has produced antibodies in response. This typically means there is or has been an infection with H. pylori, which may require further medical evaluation and treatment. Conditions Associated with Elevations Elevated levels of Helicobacter pylori antibodies in the serum are associated with: Peptic Ulcer Disease: H. pylori is a major cause of peptic ulcers, which are sores that develop on the lining of the stomach, small intestine, or esophagus. Chronic Gastritis: Long-term infection can lead to chronic inflammation of the stomach lining. Gastric MALT Lymphoma: This type of stomach cancer is linked to chronic H. pylori infection. Gastric Cancer: Persistent infection with H. pylori increases the risk of developing gastric adenocarcinoma. Treatment Considerations If a patient tests positive for H. pylori antibodies, the following treatment options are typically considered: Antibiotic Therapy: A combination of antibiotics, such as clarithromycin, amoxicillin, or metronidazole, is often prescribed to eradicate the bacteria. Proton Pump Inhibitors (PPIs): These medications, like omeprazole, reduce stomach acid, helping to heal the stomach lining. Bismuth Subsalicylate: Sometimes included in treatment regimens to protect the stomach lining and improve antibiotic effectiveness. Follow-Up Testing: After completing treatment, follow-up tests such as the urea breath test, stool antigen test, or endoscopy may be recommended to confirm eradication of the bacteria. Correlated Panels Other biomarker panels that may be correlated with H. pylori infection include: Urea Breath Test: Measures isotopic carbon dioxide in the breath after ingestion of a urea solution. Stool Antigen Test: Detects H. pylori antigens in a stool sample. Gastric Biopsy: Obtained via endoscopy to directly visualize and test stomach tissue for H. pylori. Nutrient Associations H. pylori infection can impact nutrient absorption, leading to deficiencies such as: Iron: Chronic gastritis can cause decreased iron absorption, leading to anemia. Vitamin B12: H. pylori can interfere with the stomach’s ability to absorb vitamin B12, potentially leading to deficiency and associated symptoms like fatigue and neurological issues. Vitamin C: The bacteria can reduce the stomach’s acid environment, affecting vitamin C absorption. References Marshall, B. J., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet, 323(8390), 1311-1315. Suerbaum, S., & Michetti, P. (2002). Helicobacter pylori infection. New England Journal of Medicine, 347(15), 1175-1186. Malfertheiner, P., et al. (2012). Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut, 61(5), 646-664. Testerman, T. L., & Morris, J. (2014). Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World Journal of Gastroenterology: WJG, 20(36), 12781.

Hepatitis B surface antibody level, measured in mIU/mL.

Detects lupus anticoagulants.

related to common skin disorder

Histamine is a substance that is produced by the body as part of an allergic reaction.

What is Histamine? Histamine is a natural chemical compound produced by your body. It plays essential roles in your immune system, digestion, and nervous system. It’s often associated with allergic reactions but also has other important functions: → Immune System: Histamine is released by immune cells (mast cells and basophils) during allergic reactions and inflammatory responses. → Digestive System: It stimulates stomach acid production to help digest food. → Nervous System: Histamine acts as a neurotransmitter, affecting alertness, sleep-wake cycles, and other brain functions. What is the "Histamine, Whole Blood" Test? This test measures the amount of histamine circulating in your bloodstream. It is often used to evaluate: → Allergic Reactions: Diagnosing and monitoring severe allergic responses, including anaphylaxis. → Mast Cell Disorders: Identifying conditions like mast cell activation syndrome (MCAS) or mastocytosis. → Methylation Status: Histamine levels may indicate how well your body performs a chemical process called methylation. Elevated histamine suggests under-methylation, while low levels may indicate over-methylation. Key Takeaways: → What does elevated histamine mean? Elevated histamine levels may indicate allergies, mast cell disorders, or under-methylation. → What are symptoms of high histamine? Common symptoms include hives, itching, headaches, and digestive issues. → How to lower histamine levels? Consider antihistamines, a low-histamine diet, and addressing triggers like allergens or inflammation. By working with your healthcare provider, you can better understand and address elevated histamine levels, leading to improved health and symptom management. References: 1. "Two major pathways metabolize most (>97%) of the synthesized histamine, histamine-N-methyltransferase (50 to 80%) and diamine oxidase (15 to 30%) and only 2 to 3% is excreted unchanged"[1]. 2. "Modulation of histamine's effect occurs through four types of receptors: H1, H2, H3, and H4. Histamine receptors are G-protein coupled receptors, which are 7-transmembrane chain proteins that mediate the effect of several molecules"[1]. 3. "Activation of H4 receptors by histamine stimulates the synthesis of IL-4 and IL-5 in human cord blood mast cells and tumor necrosis factor (TNF)-α in bone marrow-derived murine mast cells (BMMCs), both of which have a potential role in inducing allergic inflammation"[2][3]. 4. "In mice, deletion of H1R leads to the release of Th2 cytokines (IL-4 and IL-13) and inhibition of IFN-γ"[2][3]. 5. "Knockdown of H2R −/− mice show impaired immune functions, gastric acid secretion, and cognitive function associated with hippocampal potentiation impairments and nociception abnormalities"[2][3]. 6. "Histamine (2-[3H-imidazol-4-yl]ethanamine) is an important chemical mediator that causes vasodilation and increased vascular permeability and may even contribute to anaphylactic reactions"[4]. 7. "Within the gastrointestinal tract, histamine is present at relatively high concentrations, particularly during inflammatory responses"[5]. Links: [1] https://www.ncbi.nlm.nih.gov/books/NBK557790/ [2] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01873/full [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC6099187/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC6129797/ [5] https://onlinelibrary.wiley.com/doi/10.1111/all.12330 [6] https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.680214/full [7] https://www.nature.com/articles/s41467-023-44477-4 [8] https://onlinelibrary.wiley.com/doi/10.1155/2018/9524075

distinguishes drug-induced lupus from other lupus variants and autoimmune conditions

used in the evaluation of genetic risk for Ankylosing Spondylitis, uveitis, and several other autoimmune disorders.

Transforming growth factor beta 1, a platelet-rich signaling protein.

essential in diagnosing and managing allergic diseases

What is IgG (Immunoglobulin G)? Immunoglobulin G (IgG) is the most abundant type of antibody in your blood and body fluids. It plays a central role in your immune system’s defense against infections, especially bacterial and viral pathogens. IgG antibodies are produced by B cells in response to foreign invaders. Once produced, they help neutralize pathogens, trigger other immune cells to attack, and form long-term immune memory—which is the basis of how vaccines work. The “RDL” in the test name refers to Rheumatology Diagnostics Laboratory, a specialized lab that often analyzes autoimmune and immunologic markers. Why is IgG tested? An IgG blood test helps evaluate how well your immune system is functioning. It may be ordered to investigate: Frequent or severe infections (suggesting immunodeficiency) Autoimmune conditions (suggesting overactivity or dysregulation) Chronic inflammation Monoclonal gammopathies or plasma cell disorders (e.g., multiple myeloma) Monitoring after immunoglobulin therapy or bone marrow transplant It’s also commonly measured alongside IgA and IgM as part of a quantitative immunoglobulin panel. What does a high IgG result mean? An elevated IgG level can indicate that your immune system is overactive or responding to chronic infection, inflammation, or autoimmune disease. Common causes of elevated IgG include: 1. Chronic Infections Tuberculosis Chronic hepatitis (especially hepatitis B or C) HIV/AIDS (in some phases) Fungal or parasitic infections 2. Autoimmune Diseases Lupus (SLE) Rheumatoid arthritis Autoimmune hepatitis Sarcoidosis 3. Chronic Inflammation or Immune Activation Chronic allergic conditions Inflammatory bowel disease (IBD) Chronic lung or liver disease 4. Monoclonal or Polyclonal Gammopathies Multiple myeloma or MGUS (monoclonal gammopathy of undetermined significance) In these cases, IgG may be elevated due to uncontrolled production by abnormal plasma cells. What does a low IgG result mean? A low IgG level may suggest that your immune system can’t produce enough antibodies, leaving you vulnerable to infections. Possible causes of low IgG include: 1. Primary Immunodeficiencies Common Variable Immunodeficiency (CVID) X-linked agammaglobulinemia Selective IgG subclass deficiency 2. Secondary Immunodeficiencies Chronic lymphocytic leukemia (CLL) Immunosuppressive therapies (e.g., chemotherapy, corticosteroids) Nephrotic syndrome (IgG lost in urine) Protein-losing enteropathy Bone marrow failure or transplant People with low IgG often have frequent respiratory infections, chronic sinusitis, or pneumonia and may require immunoglobulin replacement therapy (IVIG or SCIG). What does a normal IgG result mean? A normal IgG level suggests your immune system is producing antibodies appropriately and there’s no current evidence of a major immune deficiency or hyperactivity. However, normal levels don’t always rule out disease—clinical symptoms and other lab findings are essential to the full picture. What happens next if your IgG is abnormal? If IgG is elevated: Your doctor may order additional testing, such as: IgA, IgM, and IgE levels Autoimmune panels (ANA, RF, dsDNA) Protein electrophoresis (SPEP/UPEP) to detect monoclonal spikes Infectious disease screening You may be referred to a rheumatologist, infectious disease specialist, or hematologist If IgG is low: Your provider may: Order IgG subclass testing Evaluate your infection history Consider immunoglobulin replacement therapy if infections are frequent Refer you to an immunologist Bottom Line IgG (Immunoglobulin G) is a vital part of your immune defense system. Abnormal levels—either too high or too low—can be a sign of chronic infection, autoimmune activity, immune deficiency, or other systemic conditions. Whether you're experiencing frequent infections or unexplained inflammation, this test offers critical insight into how your immune system is functioning and what steps may be needed next.

indicative for lupus nephritis and other conditions/ inflammatory diseases

identifies the type of immunoglobulin protein(s) present as monoclonal bands

Total IgA antibody concentration in serum (quantitative)

Antibody in blood

Immunoglobulin E (IgE) plays a critical role in the body's immune response, particularly in allergic reactions and certain immune disorders. As a vital component of the immune system, IgE is a type of antibody that is primarily involved in defending the body against parasitic infections and is most commonly recognized for its association with allergic diseases. Testing for IgE levels is an essential diagnostic tool in the field of allergy and immunology, offering insights into an individual's allergic sensitivities and immune system function. The primary reason to test for IgE is for the diagnosis and management of allergic diseases. When an individual is exposed to an allergen, such as pollen, pet dander, certain foods, or insect stings, their immune system may overreact, producing elevated levels of IgE. This overproduction can lead to various allergic symptoms, ranging from mild, such as sneezing and itching, to severe, like anaphylaxis, a potentially life-threatening reaction. By measuring IgE levels, healthcare professionals can identify specific allergens causing these reactions, enabling them to develop personalized treatment plans, including avoidance strategies, medication, and immunotherapy. Furthermore, IgE testing is vital for monitoring the effectiveness of allergy treatments. For patients undergoing therapies like desensitization or immunotherapy, changes in IgE levels can indicate how well the body is responding to the treatment. In chronic allergic conditions like asthma and atopic dermatitis, IgE tests help in confirming the diagnosis and assessing the severity of the condition, guiding the treatment approach. In addition to its role in allergies, IgE is also being studied for its involvement in certain immune system disorders and autoimmune diseases. Elevated IgE levels may be indicative of other underlying health issues, making it a valuable marker in broader immunological assessments.

Antibody related to allergies

Measures the total concentration of IgG in serum.

Measures the total concentration of IgM in serum.

What Is Interferon-gamma (IFN-γ)? Interferon-gamma (IFN-γ or IFNG) is a critical cytokine in the immune system, essential for both innate and adaptive immunity. It is the only member of the type II interferon family and is primarily produced by natural killer (NK) cells, T helper 1 (Th1) cells, and cytotoxic T lymphocytes. Key Roles and Functions of IFN-γ Immune Regulation IFN-γ activates macrophages and boosts the immune system's ability to recognize threats. It enhances antigen presentation by increasing the expression of MHC class II molecules, which are essential for immune recognition. Antiviral Activity First identified for its ability to inhibit viral replication, IFN-γ remains a key player in controlling viral infections. It works by activating both direct antiviral mechanisms and broader immune responses. Anti-tumor Effects IFN-γ promotes anti-tumor immunity by enhancing the activity of immune cells and supporting tumor regression. Pleiotropic Effects This cytokine influences the activity of up to 30 genes, leading to diverse cellular and physiological responses. Cell-mediated Immunity IFN-γ plays a crucial role in coordinating interactions between lymphocytes and endothelial cells. It regulates the balance between Th1 and Th2 immune responses, critical for fighting infections and managing immune reactions. Inflammation Modulation In inflammatory environments, IFN-γ stimulates the production of other cytokines, such as IL-1, amplifying immune responses. How IFN-γ Works IFN-γ exerts its effects by binding to its specific receptor, IFN-γR, found on both immune and non-immune cells. This interaction triggers signaling pathways that regulate gene expression and drive immune responses. Why Is IFN-γ Important? Understanding IFN-γ helps us grasp how the immune system fights infections, manages inflammation, and combats cancer. Its functions are also crucial in autoimmune diseases, where immune responses may be dysregulated. This knowledge is valuable for developing therapies targeting IFN-γ or its signaling pathways.

Influenza Type A antibody serum refers to the specific antibodies present in the blood serum that are directed against Influenza virus Type A, a highly variable virus responsible for seasonal flu epidemics and occasional pandemics. These antibodies are part of the body's adaptive immune response, produced by B cells as a defense mechanism following exposure to the virus or vaccination. The presence and concentration of these antibodies can be quantified through serological assays, such as hemagglutination inhibition (HI) assays, neutralization tests, and enzyme-linked immunosorbent assays (ELISA). The detection and quantification of Influenza Type A antibodies are crucial for several purposes: epidemiological surveillance, to assess the spread and impact of the virus in populations; vaccine efficacy studies, to evaluate the immune response elicited by flu vaccines; and individual diagnosis, to understand a person's immune status or history of exposure to the virus. The immune response to Influenza Type A is particularly challenging to manage and study due to the virus's ability to undergo antigenic drift and shift, leading to frequent emergence of new strains to which the population may have limited immunity. Antigenic drift involves minor changes in the virus's hemagglutinin (HA) and neuraminidase (NA) proteins, necessitating annual updates to the influenza vaccine. Antigenic shift, a more drastic change, can result in new influenza A subtypes potentially leading to pandemics. Monitoring antibody levels in the population is therefore essential for anticipating and mitigating the impact of seasonal epidemics and pandemics. Furthermore, understanding the dynamics of antibody production, maintenance, and waning after infection or vaccination provides insights into the development of more effective vaccines and therapeutic strategies.

The marker "Influenza Type B Antibody Serum" refers to the presence of specific antibodies in the serum that are produced in response to infection with Influenza Type B virus or following vaccination against this virus. These antibodies are a crucial component of the immune response and serve as indicators of an individual's exposure to the virus or their immunization status. Influenza Type B is one of the three main types of influenza viruses (alongside Types A and C) that infect humans and can cause seasonal epidemics of disease. The presence of these antibodies is detected through serological assays, which are laboratory tests that measure the concentration of antibodies in the blood serum. These tests can differentiate between Type A and Type B influenza infections due to the antigenic differences between the two types. The detection of Influenza Type B antibodies in serum not only aids in the diagnosis of recent or past infections but also helps in epidemiological surveillance and in assessing the effectiveness of influenza vaccines. As the influenza virus can undergo antigenic changes, monitoring the antibody levels in populations is vital for vaccine formulation and public health planning to mitigate the impact of seasonal outbreaks.

Interleukin-10 (IL-10) is a key anti-inflammatory cytokine that helps regulate the immune system and prevent excessive inflammation. It is released by immune cells to calm inflammatory responses and protect tissues after the immune system has been activated by infection, injury, or stress. IL-10 testing provides insight into the body’s immune regulation and recovery processes. Although IL-10 does not diagnose specific diseases on its own, it is often measured alongside other inflammatory markers to understand overall immune activity and balance. Equivocal or borderline IL-10 results can occur when levels are near the reference cutoff. This may mean that immune-regulatory activity is shifting or that the body is in a transitional phase — such as early recovery from infection, low-grade inflammation, or stress-related immune modulation. In these cases, clinical context and additional markers (such as CRP, IL-6, TNF-α, and complete immune panels) help clarify the significance of the result. This marker is especially relevant when assessing chronic inflammation, immune-related conditions, or the body's response after acute immune activation.

Interleukin 2 (IL-2) is a pleiotropic (=having multiple effects from a single gene) cytokine produced primarily by mitogen- or antigen- activated T lymphocytes. Interleukin 2 plays a role in promoting the clonal expansion of antigen-specific cytotoxic and suppressor T cells. In vitro studies suggest that Interleukin 2 may also be produced by dendritic cells and certain lymphoma cell lines. In addition, IInterleukin 2 has been shown to mediate multiple immune responses on a variety of cell types. Interleukin 2 stimulates the proliferation of thymocytes; stimulates the proliferation and differentiation of activated B cells; promotes the growth, differentiation, and cytocidal activity of monocytes; induces the growth of natural killer cells and stimulates cytokine production by these cells, as well as enhancing the cytolytic activity of these cells; enhances the production of lymphocyte-activated killer (LAK) cells; and induces the proliferation and differentiation of oligodendrocytes. References: - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728644/

Interleukin-6 is involved in inflammation and infection responses and also in the regulation of metabolic, regenerative, and neural processes.

Inflammation signaling cytokine

High levels in chronic inflammatory diseases

This test measures the amount of antibodies to anti-Jo-1 in blood.

associated with polymyositis and may also be seen in patients with dermatomyositis

to help detect, diagnose, and monitor conditions associated with an increased production of free light chains.

Liver-Kidney Microsome IgG antibody (anti-LKM), as detected by indirect immunofluorescent antibody (IFA) techniques, may be observed in patients with autoimmune hepatitis type 2 (AIH-2), AIH-2 associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), viral hepatitis C or D, and some forms of drug-induced hepatitis. This IFA does not differentiate among the four types of LKM antibodies (LKM-1, LKM-2, LKM-3, and a fourth type that recognizes CYP1A2 and CYP2A6 antigens). Of these, anti-LKM-1 (cytochrome P450IID6) IgG antibodies are considered specific for AIH-2.

Used in the evaluation of patients suspected of having autoimmune hepatitis.

Risk of forming blood clots

Serum lysozyme has emerged as a valuable biomarker for monitoring disease progression and regression, particularly in cases of confirmed sarcoidosis. According to revised FAB (French, American, British) criteria, serum or urine lysozyme levels that are three times the normal limit fulfill one of the key diagnostic criteria for distinguishing M4/M5 acute myeloid leukemia with monocytic differentiation from M2 acute myeloblastic leukemia with maturation. Lysozyme is a hydrolytic enzyme and bacteriolytic glycosidase, which, when present in high concentrations, can be detected as a distinctive cationic band during serum or urine protein electrophoresis. This enzyme is found in all three types of human neutrophil granules—azurophil, specific, and gelatinase. It is frequently elevated in cases of myelogenous leukemia and is notably increased in most instances of myelomonocytic and monocytic leukemia. The degree of elevation is proportional to the extent of monocytic differentiation and the overall tumor cell burden. Significant increases in lysozyme levels can lead to complications such as potassium wasting and hypokalemia. Immunoelectron microscopy has also detected lysozyme within the granules of both normal and leukemic eosinophils. However, elevated serum lysozyme levels alone may not conclusively indicate monocytic differentiation in acute myelogenous leukemia cases with eosinophilia. Importantly, serum lysozyme levels have also been utilized to predict central nervous system involvement in these types of leukemias. In addition to leukemia, elevated serum lysozyme levels have been observed in various conditions, including tuberculosis and sarcoidosis. In a recent study, the sensitivity of serum lysozyme for predicting sarcoidosis was found to be 79%, significantly higher than the 59% sensitivity for serum angiotensin-converting enzyme (ACE) in the same study. Furthermore, lysozyme levels were shown to increase with the number of organs involved in sarcoidosis, although its specificity for the condition is lower compared to serum ACE. A turbidimetric method for measuring serum lysozyme activity has proven useful for distinguishing between infection and rejection in transplant recipients, further underscoring its diagnostic versatility.

Mannose Binding Lectin (MBL) is a key biomarker in the innate immune system, playing a crucial role in the body's first line of defense against pathogens. It is a pattern recognition molecule that binds specifically to carbohydrate structures, such as mannose and other sugars, found on the surface of a wide range of microorganisms, including bacteria, viruses, fungi, and parasites. Upon binding, MBL activates the lectin pathway of the complement system, leading to enhanced opsonization of the pathogen, phagocytosis, and eventual lysis or clearance of the invader. MBL deficiency or low levels can lead to increased susceptibility to infections, particularly in individuals with weakened immune systems or underlying health conditions. Low MBL levels are linked to a higher risk of recurrent respiratory infections, autoimmune diseases, and some chronic conditions. However, many people with MBL deficiency remain asymptomatic due to compensation by other immune pathways. Measuring MBL levels in blood can help assess susceptibility to infections or monitor immune system health, especially in immunocompromised patients. Research into MBL is also exploring its potential role in conditions such as sepsis, chronic inflammation, and even cardiovascular diseases. While there are no specific treatments for MBL deficiency, managing infections and supporting immune health through preventive measures like vaccines and proper hygiene can help reduce the risk of complications.

Determining immune status of individuals to the measles virus

Determination of postimmunization immune response of individuals to the mumps vaccine

Pepsinogen A2 Globulin

associated with an increased odds ratio for thrombosis.

associated with an increased odds ratio for thrombosis.

associated with an increased odds ratio for thrombosis.

For assessing thrombotic risk and other obstetric complications such as miscarriage or fetal growth restriction

For assessing thrombotic risk and other obstetric complications such as miscarriage or fetal growth restriction

For assessing thrombotic risk and other obstetric complications such as miscarriage or fetal growth restriction

a serine protein inhibitor that is secreted in response to inflammatory reactions.

What is the Pooled Donor – BAT CU test? Pooled Donor – BAT CU is part of a specialized blood test panel used to evaluate the autoimmune activity underlying chronic spontaneous urticaria (CSU)—a condition marked by persistent hives, itching, and swelling that lasts for more than 6 weeks without an obvious allergic cause. The “BAT” stands for Basophil Activation Test, and this specific version uses pooled donor basophils—white blood cells from healthy individuals—to assess whether your serum contains autoantibodies or factors that can trigger allergic-like immune activation. What does this marker measure? This test looks at how your blood (serum) interacts with donor basophils to see if it causes them to become activated. When basophils are activated, they release histamine and other chemicals that cause hives and swelling. A positive Pooled Donor BAT CU result means your immune system is likely producing substances—often autoantibodies against IgE or its receptor (FcεRI)—that activate basophils and may be driving your chronic urticaria. What does a positive result mean? If your Pooled Donor – BAT CU result is elevated or positive, it suggests: Your chronic hives may have an autoimmune basis (autoimmune CSU) Your immune system is likely triggering your symptoms without a known allergen You may respond better to certain treatments, such as: Omalizumab (an anti-IgE biologic) Immunosuppressive therapy in severe, refractory cases Longer treatment duration may be required compared to non-autoimmune urticaria This result provides insight into why your hives are occurring, especially when skin prick or allergy tests come back negative. What does a negative result mean? A negative BAT CU result indicates that no significant activation of donor basophils occurred in response to your serum. This may suggest: Your chronic urticaria is not autoimmune-driven, or Autoantibodies are present at levels too low to detect Another mechanism, such as non-specific mast cell activation, may be responsible Even with a negative result, treatment is still available and often includes antihistamines, leukotriene receptor antagonists, or biologics like omalizumab. Next Steps After Testing If your result is positive: Your provider may classify your urticaria as autoimmune chronic spontaneous urticaria This can help guide more effective treatment options and set realistic expectations You may be monitored more closely for treatment resistance or systemic involvement If your result is negative: Other causes of chronic hives may be explored, including non-autoimmune triggers, stress, infections, or environmental factors Bottom Line The Pooled Donor – BAT CU test helps uncover whether autoimmune activity is triggering your chronic hives. A positive result supports a diagnosis of autoimmune urticaria, helping your doctor choose treatments that work better for your specific immune profile. If you’ve been struggling with hives for weeks or months without answers, this test can offer important insights.

Procalcitonin is a marker of significant interest in the medical field, particularly when it comes to diagnosing and managing infections. Produced in response to a bacterial infection, procalcitonin levels in the blood can help doctors determine the severity of an infection or sepsis, a life-threatening response to infection. Unlike other markers that may rise in various conditions, procalcitonin is relatively specific to bacterial infections, making it a valuable tool for clinicians. When a patient presents symptoms of an infection, measuring procalcitonin levels can aid in deciding whether antibiotics are needed, as elevated levels are often indicative of a bacterial cause. On the other hand, low levels of procalcitonin might suggest a viral infection or another non-bacterial cause, potentially guiding a clinician away from unnecessary antibiotic use. This distinction is crucial in the fight against antibiotic resistance, a growing concern in healthcare. Labs, like Labcorp, offer procalcitonin testing, providing clinicians with a quantitative measure of procalcitonin in the blood. This information, in conjunction with other clinical findings, helps healthcare providers make more informed decisions about diagnosis, the necessity of antibiotics, and, if used, monitoring the effectiveness of treatment. The use of procalcitonin as a biomarker is a testament to how advanced laboratory testing contributes to personalized and precise patient care. This marker is useful: → to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock; → to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission; → to aid in decision making on antibiotic therapy, for inpatients or patients in the emergency department with suspected or confirmed lower respiratory tract infections (LRTI) — defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD); → to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.

a crucial biomarker for cell proliferation and DNA maintenance

to check for latent tuberculosis (TB) infection

Rheumatoid arthritis test

Von Willebrand Factor Collagen Binding Activity Ratio (vWF:CB/vWF:Ag) The von Willebrand Factor Collagen Binding Activity to von Willebrand Factor Antigen ratio (vWF:CB/vWF:Ag) is a critical diagnostic parameter in the evaluation of von Willebrand Disease (VWD). This ratio provides essential information about the functional quality of von Willebrand Factor molecules relative to their quantity in circulation. Understanding the Ratio The vWF:CB/vWF:Ag ratio is calculated by dividing the collagen binding activity result by the von Willebrand Factor antigen level. A normal ratio typically falls between 0.7 and 1.2, though laboratory-specific reference ranges may vary. This ratio effectively normalizes the functional activity of vWF to its antigenic level, helping clinicians distinguish between quantitative and qualitative defects. Clinical Significance The ratio serves as a valuable diagnostic tool in several ways: When the ratio is normal (≥0.7) but both values are proportionally decreased, this suggests Type 1 VWD, characterized by a quantitative deficiency where the existing vWF functions normally. In contrast, a decreased ratio (<0.7) with normal or low absolute values typically indicates Type 2 VWD, reflecting a qualitative defect in vWF function. Notably, a very low ratio may specifically suggest Type 2A or 2B VWD, where there is a selective loss of high-molecular-weight multimers. Interpretation Considerations Several factors can influence ratio interpretation. These include age, blood type, acute phase reactions, and certain medications. The ratio should always be interpreted within the context of other laboratory findings, clinical presentation, and patient history. Serial measurements may be necessary to establish consistent patterns, particularly in complex cases or when monitoring treatment response. Applications in Patient Management Clinicians use the vWF:CB/vWF:Ag ratio to guide treatment decisions and monitor therapeutic interventions. The ratio helps determine the most appropriate treatment approach, whether it involves desmopressin (DDAVP) or factor replacement therapy. During treatment, changes in the ratio can indicate therapeutic effectiveness and help adjust dosing regimens. Technical Aspects The accuracy of the ratio depends on precise measurement of both parameters. Modern automated platforms have improved standardization and reproducibility, but inter-laboratory variation remains a consideration. Quality control measures and regular calibration are essential for reliable ratio determination. Future Perspectives Ongoing research aims to refine the diagnostic utility of the vWF:CB/vWF:Ag ratio. Areas of investigation include establishing more precise cutoff values for different VWD subtypes, understanding the ratio's predictive value for bleeding risk, and developing standardized approaches to ratio interpretation across different laboratory methods and patient populations. In conclusion, the vWF:CB/vWF:Ag ratio represents a sophisticated tool in the diagnosis and classification of VWD. Its careful interpretation, alongside other clinical and laboratory parameters, enables more accurate disease characterization and improved patient care.

measures the rate of fibrin clot formation after the addition of reptilase

RF, IgA by EIA (RDL) refers to the measurement of rheumatoid factor (RF) of the IgA subclass using an enzyme immunoassay (EIA), typically performed at RDL (Reference Diagnostic Laboratory). RF is an autoantibody directed against the Fc portion of immunoglobulin G (IgG) and is commonly associated with rheumatoid arthritis (RA) and other autoimmune conditions. While IgM-RF is the most commonly tested form, IgA-RF may provide additional diagnostic value, particularly in seronegative RA or cases with extra-articular manifestations. Elevated IgA-RF levels have been linked to more severe joint damage and systemic inflammation, and they may correlate with disease activity in rheumatoid arthritis and other autoimmune disorders. This test is typically used alongside other serological markers like IgM-RF, anti-CCP antibodies, and inflammatory markers to improve diagnostic accuracy and assess disease progression.

RF, IgG by EIA (RDL) refers to the measurement of rheumatoid factor (RF) of the IgG class using enzyme immunoassay (EIA) at RDL (Rheumatology Diagnostic Laboratory). Rheumatoid factor is an autoantibody that targets the Fc region of IgG, and its presence is often associated with autoimmune conditions, particularly rheumatoid arthritis (RA) and other inflammatory diseases. While RF is most commonly measured as IgM, the IgG RF subtype can also contribute to disease mechanisms, including immune complex formation and chronic inflammation. Elevated IgG RF levels may indicate rheumatoid arthritis, Sjögren’s syndrome, or other connective tissue diseases, but can also be found in some infections and chronic inflammatory states. Since RF alone is not diagnostic, it is typically interpreted alongside other markers, such as anti-CCP antibodies, ESR, and CRP, to assess autoimmune disease activity.

RF, IgM by EIA (RDL) is a laboratory test that measures rheumatoid factor (RF) of the IgM class using enzyme immunoassay (EIA) methodology. RF is an autoantibody that targets the Fc region of IgG antibodies and is commonly associated with autoimmune conditions, particularly rheumatoid arthritis (RA). Elevated RF IgM levels can indicate inflammatory or autoimmune diseases, including Sjogren’s syndrome, systemic lupus erythematosus (SLE), and other connective tissue disorders. However, RF can also be detected in some healthy individuals or those with chronic infections, making it important to interpret results alongside clinical symptoms and other diagnostic markers. The RDL designation refers to the reference diagnostic laboratory performing the test, ensuring standardized measurement and reliability.

often used to help diagnose rheumatoid arthritis (RA)

Rheumatoid Factor (IgA) – What It Means in Your Lab Results Rheumatoid Factor (RF) IgA is an IgA-class autoantibody that targets the Fc region of other immunoglobulins, similar to RF IgG and IgM. While RF (IgM) is the most commonly tested marker for rheumatoid arthritis (RA), RF (IgA) may provide additional insights into disease severity, progression, and immune system activity. Why Is RF IgA Measured? This test is useful for: Diagnosing and assessing rheumatoid arthritis (RA) – Especially in seronegative patients (those who test negative for RF IgM but still have RA symptoms). Evaluating disease severity – RF IgA is linked to more aggressive joint damage and extra-articular (outside the joints) manifestations of RA. Distinguishing autoimmune conditions – Helps differentiate RA from other inflammatory disorders. What Do Elevated RF IgA Levels Mean? Rheumatoid Arthritis (RA) Elevated RF IgA is often found in RA, particularly in more severe or erosive disease. High levels may indicate a greater risk of joint destruction, systemic inflammation, and lung involvement (rheumatoid lung disease). Other Autoimmune Diseases Sjogren’s Syndrome – A condition affecting moisture-producing glands, often with high RF IgA. Systemic Lupus Erythematosus (SLE) – RF IgA can be elevated in some lupus cases. Ankylosing Spondylitis & Psoriatic Arthritis – Occasionally associated with RF IgA positivity. Chronic Infections & Other Conditions Chronic Viral or Bacterial Infections – Hepatitis B/C, tuberculosis, and endocarditis can trigger RF IgA production. Mucosal Inflammation & IgA-Related Disorders – Since IgA is associated with mucosal immunity, conditions like IgA nephropathy, celiac disease, or inflammatory bowel disease (IBD) may show mild RF IgA elevation. Aging & Non-Autoimmune Conditions – Some older adults may have low-level RF IgA without any disease. How RF IgA Differs From RF IgM and IgG RF IgM is the most common marker for RA and is often used for diagnosis. RF IgG may be elevated in RA but is also linked to chronic infections and inflammatory conditions. RF IgA is more closely associated with disease severity, joint erosions, and extra-articular RA symptoms. Next Steps if RF IgA Is Elevated Further Testing: Anti-CCP antibodies – More specific for RA. CRP & ESR – Measure inflammation levels. Imaging (X-ray/MRI) – To assess joint damage. Clinical Correlation: Symptoms like morning stiffness, joint swelling, fatigue, and lung issues help determine if RA or another condition is present. Monitoring Over Time: RF IgA levels may fluctuate, and a high result alone does not confirm a diagnosis.

Rheumatoid Factor (IgG) – What It Means in Your Lab Results Rheumatoid Factor (RF) IgG is an immunoglobulin G (IgG) autoantibody that targets the body’s own tissues, particularly the Fc region of other antibodies. While RF is commonly associated with rheumatoid arthritis (RA), its presence can also indicate other autoimmune conditions or chronic infections. Why Is RF IgG Measured? This test helps evaluate: Autoimmune diseases – Particularly rheumatoid arthritis (RA) and other inflammatory conditions. Chronic infections – Some persistent infections may trigger RF production. Other connective tissue disorders – Such as Sjogren’s syndrome or systemic lupus erythematosus (SLE). Understanding Your Results Elevated RF IgG may indicate rheumatoid arthritis, though it is not specific to RA. It can also be present in other autoimmune diseases or even in healthy individuals, particularly with aging. Low or undetectable RF IgG is generally normal but does not rule out autoimmune disease, as some patients with RA can be seronegative (lacking detectable RF). How RF IgG Differs from RF (IgM)? The IgM form of RF is the most commonly tested in standard panels for rheumatoid arthritis, but IgG RF may provide additional insight into immune system activity, especially in early RA or other immune-mediated conditions. Next Steps If RF IgG is elevated, further testing (such as anti-CCP antibodies, inflammatory markers like CRP and ESR) may be needed to clarify the diagnosis. Your healthcare provider will interpret results in the context of your symptoms and medical history.

RF-IgM tests for rheumatoid arthritis antibodies. Elevated may suggest RA or autoimmune conditions — but positive results always need clinical context. HealthMatters.

Ristocetin Cofactor (RCoF) Test: Essential for Diagnosing von Willebrand Disease The Ristocetin Cofactor (RCoF) test is a critical diagnostic tool used to assess the functional activity of von Willebrand factor (vWF), a glycoprotein vital for blood clotting and primary hemostasis. This test is pivotal in diagnosing and managing von Willebrand disease (VWD), the most common inherited bleeding disorder, which affects up to 1% of the global population. How the RCoF Test Works The RCoF assay measures how well vWF binds to platelets to promote clot formation. Using ristocetin, a glycopeptide antibiotic, the test induces platelet aggregation in the presence of functional vWF. The degree of platelet clumping reflects vWF activity, providing a quantitative measure of its function. Key Features and Benefits Specificity: Targets vWF functionality, unlike other coagulation tests. Sensitivity: Effective in detecting type 2 VWD, where vWF is present but dysfunctional. Complementary Testing: Often paired with vWF antigen (vWF:Ag) tests to distinguish between quantitative (low vWF levels) and qualitative (dysfunctional vWF) defects. Clinical Applications The RCoF test is invaluable for: Diagnosing all types of VWD (types 1, 2, and 3). Monitoring treatment efficacy in VWD patients. Assessing bleeding risks before surgery. Detecting acquired von Willebrand syndrome in patients with other medical conditions. Limitations and Interpretation Low RCoF levels may indicate: Von Willebrand disease (types 1, 2, or 3). Acquired von Willebrand syndrome. Platelet function disorders. However, factors such as blood type, stress, and pregnancy can influence results. Thus, the RCoF test should always be interpreted alongside clinical findings and other lab results. Innovations in RCoF Testing Automated assays: Enhance reproducibility and reduce turnaround time. Recombinant ristocetin analogs: Improve test accuracy and specificity. Point-of-care testing: Enables rapid diagnosis in critical or emergency situations. Conclusion The Ristocetin Cofactor test remains a cornerstone in diagnosing and managing von Willebrand disease and related bleeding disorders. Its ability to assess the functionality of vWF makes it an indispensable resource for hematologists and hemostasis laboratories worldwide, ensuring better patient outcomes through accurate diagnosis and tailored treatment strategies.

associated with a form of autoimmune disease called scleroderma

an extractable nuclear antigen (ENA) associated MCTD

commonly associated with autoimmune diseases

antibodies to the rubella virus

COVID-19 infection antibody marker

SARS-CoV-2 Semi-Quant IgG Ab – What Your Antibody Test Really Means The SARS-CoV-2 Semi-Quantitative IgG Antibody test is a blood test that measures the level of IgG antibodies your body has produced in response to the SARS-CoV-2 virus, the virus responsible for COVID-19. Unlike a qualitative test that gives a simple “positive” or “negative” result, this semi-quantitative test estimates the amount of antibody present and provides a numerical value — giving more detailed insight into your immune system’s response. What Are IgG Antibodies? Immunoglobulin G (IgG) antibodies are part of your body’s long-term immune defense system. After a person is exposed to a virus like SARS-CoV-2 — either through natural infection or vaccination — the immune system produces IgG antibodies to help fight off future infections. These antibodies typically appear within 1 to 3 weeks after infection or immunization and may remain in the blood for months or longer, although levels naturally decline over time. Why Is This Test Done? The SARS-CoV-2 Semi-Quant IgG Ab test is often used to: Determine if you've had a past COVID-19 infection, especially if you were asymptomatic or not tested at the time. Check for an immune response after vaccination, especially in people who are immunocompromised or at high risk. Track antibody levels over time, often as part of clinical studies or public health surveillance. Provide supporting evidence when evaluating suspected long COVID or post-viral complications. It is not used to diagnose an active COVID-19 infection. For that, you would need a PCR or antigen test. Understanding Your Results Positive or Elevated Result If your test shows detectable levels of SARS-CoV-2 IgG antibodies, it means your immune system has responded to the virus or vaccine. This result may indicate: A previous infection with SARS-CoV-2, even if you didn’t have symptoms. A successful immune response to a COVID-19 vaccine. Possible short-term immunity, though protection can vary by individual and over time. Your test may include a numerical value or index — higher numbers generally mean more antibodies, but there is no universally accepted "protective level" at this time. Negative or Low Result A negative or very low IgG antibody level suggests: No prior exposure to the virus or vaccine. The test was done too early, before your body had time to produce IgG antibodies. Antibody levels have waned over time, which is common and doesn’t necessarily mean you’re no longer protected. You may not have mounted a strong immune response due to immune suppression or chronic illness. Important Notes About Interpretation Antibody presence does not guarantee immunity. It’s one part of a complex immune system that also includes T-cells and memory B cells. The type of antibodies measured matters — some tests detect antibodies to the spike (S) protein (used in most vaccines), while others detect antibodies to the nucleocapsid (N) protein (which typically indicates natural infection). The semi-quantitative format provides a relative measure, not an exact titer. It's useful for tracking trends, not confirming full immunity. Do You Need Follow-Up? Most people don’t need follow-up unless: You’re immunocompromised and your doctor is monitoring your response to the vaccine. You're being evaluated for long COVID symptoms. You’re part of a study or work in a high-risk setting like healthcare. Your healthcare provider may recommend additional testing or booster shots depending on your results and risk factors. In Summary The SARS-CoV-2 Semi-Quant IgG Ab test gives a detailed look at your immune system's history with COVID-19. A positive result typically means you’ve developed antibodies through infection or vaccination, while a negative result suggests no prior exposure or a diminished immune response. While it can offer insight into your immune status, this test is not a direct measure of immunity and should always be interpreted with your clinical history and vaccination status in mind.

The SARS-CoV-2 Spike Antibody Dilution test measures the concentration of IgG antibodies that target the spike protein of SARS-CoV-2, the virus that causes COVID-19. Unlike a simple positive/negative test, this method uses dilution to accurately detect even very high antibody levels, offering a clearer picture of your immune response. What the Test Measures This test quantifies the amount of spike-specific antibodies in your blood. These antibodies usually develop after: COVID-19 vaccination (Pfizer, Moderna, Novavax, and others) Previous COVID-19 infection When antibody levels are very high—often after vaccination or a booster—standard antibody tests can reach their upper detection limit. Dilution testing “scales down” the sample so antibody levels can be measured precisely and reliably. What Your Results Can Tell You Antibody presence: Confirms that your immune system has responded to either vaccination or infection. Relative antibody level: Higher dilution values generally reflect higher concentrations of antibodies. Immune recognition: Shows your body can recognize the spike protein, which may help mount a faster response upon re-exposure. Risk insight: People with higher antibody levels often have lower risk of severe COVID-19, though protection varies by individual and viral variant. What These Results Do Not Show Exact protection: There is no universally defined antibody threshold that guarantees immunity. Timing of exposure: This test cannot determine when you were vaccinated or infected. Active infection: The dilution test does not diagnose current COVID-19 infection; other tests are needed for that purpose. Why Dilution Testing Matters Shortly after vaccination or booster shots, antibody levels can be so elevated that standard assays cannot measure them accurately. Diluting the sample ensures your result reflects the true concentration, rather than just reporting a “maximum.” This provides a more meaningful and actionable result for both patients and healthcare providers. Summary The SARS-CoV-2 Spike Antibody Dilution test offers a precise measurement of your antibody levels against the spike protein of COVID-19. Higher results typically suggest a stronger immune response from prior vaccination or infection. However, antibody levels alone do not guarantee full protection or lasting immunity. Continue to follow current public health recommendations, as antibodies are just one part of your body’s overall defense system.

SARS-CoV-2 Spike Ab Interp – Understanding Your COVID-19 Spike Protein Antibody Test The SARS-CoV-2 Spike Ab Interp refers to the interpretation of antibodies directed against the spike (S) protein of the virus that causes COVID-19. This marker is typically included in antibody panels to evaluate your immune response following infection with SARS-CoV-2 or after vaccination with COVID-19 vaccines that target the spike protein (such as Pfizer-BioNTech, Moderna, or Novavax). This test does not measure the antibody level itself, but instead provides an interpretation (positive, negative, equivocal) based on whether spike-specific antibodies are detected in your blood. What Is the Spike Protein and Why Does It Matter? The spike protein is the part of the SARS-CoV-2 virus that allows it to attach to and enter human cells. It’s also the main target of most COVID-19 vaccines, which are designed to teach the immune system to recognize and fight this viral protein. When you are: Infected with SARS-CoV-2, your body develops antibodies to several viral proteins, including the spike and nucleocapsid (N) proteins. Vaccinated, your immune system primarily develops antibodies only against the spike protein, since that’s what the vaccine presents. The SARS-CoV-2 Spike Ab Interp helps assess whether your immune system has mounted a spike-directed antibody response — which would be expected after vaccination or infection. What Does This Test Result Mean? Positive Spike Antibody Interpretation This means spike-specific IgG antibodies were detected in your blood. It suggests: A prior COVID-19 infection, or A successful immune response to a COVID-19 vaccine. It does not distinguish between infection and vaccination — additional testing (e.g., nucleocapsid antibody test) may be needed for that. A positive result may indicate some level of immune protection, though it’s important to understand that: Antibody presence does not equal guaranteed immunity. Other immune components (e.g., T-cells) also play a role. Protection may wane over time, depending on age, health, and exposure to variants. Negative Spike Antibody Interpretation This means spike antibodies were not detected. Possible reasons include: You have never been infected or vaccinated. You were recently exposed or vaccinated, and antibodies have not yet developed (usually takes 1–3 weeks). Your antibodies have declined over time, which is common. You have an impaired immune response, which can occur with immunosuppressive conditions or treatments. Equivocal or Indeterminate Result This suggests the antibody level is borderline, and may require: Repeat testing at a later time Additional immune evaluation Clinical correlation with symptoms or history How Is This Test Used? Doctors may order SARS-CoV-2 Spike Ab Interp for several reasons: To evaluate your response to a COVID-19 vaccine, especially in immunocompromised patients. To determine if you were previously infected, especially if you never had PCR testing at the time. To help assess whether a booster vaccine might be needed (though guidelines primarily rely on timing, not antibody levels). As part of clinical studies tracking immunity in populations. Limitations to Be Aware Of This test does not diagnose active COVID-19. PCR or antigen testing is needed for that. A positive result does not guarantee immunity against future infection. The test does not measure T-cell immunity, which also contributes to long-term protection. The results may not correlate perfectly with protection against new variants of the virus. Key Takeaways SARS-CoV-2 Spike Ab Interp gives you an interpretation of whether your immune system has made antibodies against the spike protein of the COVID-19 virus. A positive result suggests prior infection or vaccination. A negative result may indicate no prior exposure, a weak immune response, or the need for more time after vaccination. The result should be interpreted in context — along with your vaccination history, symptoms, timing, and immune health.

Reference Ranges: Negative: Less than 0.20 OD. No significant level of IgG antibody to Schistosoma detected. Indeterminate: 0.20 to 0.49 OD. It is recommended to repeat the assay with a paired sample after at least one month, when the results fall within this range. Positive: Greater than or equal to 0.50 OD. Presumptive evidence of a current or past infection with Schistosoma species. Serological results should be used as an aid in diagnosis and should not be interpreted as diagnostic by themselves. The Schistosoma IgG Antibody marker on a panel from Labcorp is a diagnostic tool used to detect antibodies against Schistosoma, a type of parasitic worm that causes schistosomiasis. When someone is infected with Schistosoma, their immune system responds by producing specific antibodies, including IgG. The presence of Schistosoma IgG antibodies in a blood sample indicates that the person has been exposed to the parasite. This exposure could be recent or from a past infection since IgG antibodies can remain in the bloodstream for a long time. The test does not differentiate between current or past infections but provides valuable information about exposure. This is particularly useful in diagnosing schistosomiasis, especially in individuals who have traveled to or lived in areas where the parasite is common, such as parts of Africa, South America, the Caribbean, the Middle East, and Southeast Asia. Symptoms of schistosomiasis can include abdominal pain, diarrhea, blood in the urine or stool, and chronic infections can lead to more severe complications like liver damage, kidney failure, or bladder cancer. Therefore, a positive Schistosoma IgG Antibody test helps healthcare providers understand if schistosomiasis might be the cause of these symptoms, guiding further testing and treatment decisions. A negative result for the Schistosoma IgG Antibody test indicates that there are no detectable IgG antibodies against Schistosoma in the person's blood. This suggests that the individual has not been exposed to the Schistosoma parasite or that any previous exposure did not lead to a significant immune response detectable by the test. It is important to note, however, that a negative result does not completely rule out the possibility of a very recent infection, as it can take several weeks for IgG antibodies to develop to detectable levels. Therefore, if there is a strong suspicion of schistosomiasis based on symptoms or exposure history, additional tests or follow-up testing might be recommended. A negative result can be reassuring for individuals who have not been in regions where Schistosoma is prevalent or who do not have symptoms consistent with schistosomiasis.

aka Topoisomerase I Antibody

also known as the erythrocyte sedimentation rate (ESR)

Understanding the SEMI-QUANT RF Biomarker: A Key to Autoimmune Diagnostics The SEMI-QUANT RF (Semi-Quantitative Rheumatoid Factor) biomarker plays a critical role in the early detection and monitoring of autoimmune diseases, particularly Rheumatoid Arthritis (RA). Rheumatoid Factor (RF) is an antibody that targets the body's tissues, leading to inflammation and joint damage, a hallmark of RA. Measuring RF levels accurately is essential for guiding treatment and tracking disease progression. What Is SEMI-QUANT RF? SEMI-QUANT RF refers to a semi-quantitative assay used to measure the amount of Rheumatoid Factor in a patient's blood. Unlike qualitative tests, which simply provide a "positive" or "negative" result, the semi-quantitative RF test gives more detailed information about how much RF is present. This level of precision is important because higher concentrations of RF are often linked with more severe disease activity. Why Is SEMI-QUANT RF Important? Early diagnosis of Rheumatoid Arthritis is crucial for preventing irreversible joint damage. The SEMI-QUANT RF test helps physicians: → Diagnose RA Early: Elevated RF levels are one of the earliest signs of RA. → Monitor Disease Activity: By measuring RF levels over time, healthcare providers can assess the effectiveness of treatments and adjust therapies accordingly. → Differentiate Between Conditions: While RF is commonly associated with RA, elevated levels can also occur in other autoimmune or chronic inflammatory conditions. SEMI-QUANT RF tests can help differentiate between various disorders. How Does the SEMI-QUANT RF Test Work? The SEMI-QUANT RF test is a blood test that measures the concentration of RF antibodies. Results are typically reported as IU/mL (International Units per Milliliter). A higher concentration of RF antibodies often correlates with more aggressive disease. This test is part of a broader panel of diagnostic tools for autoimmune conditions, complementing other biomarkers like Anti-Cyclic Citrullinated Peptide (anti-CCP) and imaging techniques. Key Benefits of SEMI-QUANT RF Early Detection: SEMI-QUANT RF can detect RA before significant joint damage occurs, allowing for timely intervention. Treatment Guidance: By tracking RF levels over time, doctors can better understand how well treatments are working and adjust as needed. Comprehensive Health Insight: Alongside other diagnostic tests, SEMI-QUANT RF offers a clearer picture of a patient’s immune system activity, guiding personalized treatment plans. What Do SEMI-QUANT RF Results Mean? → Normal RF Levels: A normal or negative result does not necessarily rule out RA, especially in early stages. → Elevated RF Levels: Higher levels of RF (commonly over 14 IU/mL) are associated with autoimmune diseases such as RA. However, elevated RF can also be present in other conditions like Lupus, Sjögren’s Syndrome, and even some chronic infections. The SEMI-QUANT RF biomarker is a powerful tool in autoimmune disease management. Whether for early detection of Rheumatoid Arthritis or ongoing monitoring of disease progression, its ability to provide a detailed measurement of RF levels makes it indispensable in clinical settings. For anyone facing autoimmune disorders, knowing your SEMI-QUANT RF levels can guide more personalized and effective care. Keywords: SEMI-QUANT RF, Rheumatoid Factor, autoimmune diseases, rheumatoid arthritis, RF blood test, biomarker for RA, early detection RA, autoimmune diagnostic tests, SEMI-QUANT test

a vital medical procedure designed to detect sickle cell disease

specific for lupus erythematosus (LE)

an extractable nuclear antigen (ENA) associated MCTD

Smith/RNP (ENA) antibodies, predominantly of the IgG class, are a significant marker in the diagnostic landscape of autoimmune diseases, particularly systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). These antibodies target specific proteins found in the cell nucleus, making them a crucial component in the array of antinuclear antibodies (ANAs) often tested for in autoimmune diagnostics. In the context of SLE, the presence of Smith/RNP antibodies is relatively rare but highly specific. This means that while not all SLE patients have these antibodies, those who do are very likely to have SLE. This specificity makes Smith/RNP antibodies an invaluable tool in distinguishing SLE from other autoimmune disorders, which can often present with similar symptoms. On the other hand, in MCTD, these antibodies play a more central role. MCTD is characterized by symptoms that overlap with several other connective tissue diseases, including SLE, scleroderma, and polymyositis. The presence of high levels of Smith/RNP antibodies is a key factor in diagnosing MCTD, as it helps to delineate this condition from its counterparts. Testing for Smith/RNP antibodies is typically done through blood tests, where IgG antibodies are detected using techniques such as enzyme-linked immunosorbent assay (ELISA) or immunofluorescence. A positive test result for these antibodies, especially when correlated with clinical symptoms, can be a decisive factor in the diagnosis and management of autoimmune disorders. Understanding the role of Smith/RNP (ENA) antibodies, IgG in autoimmune diseases is crucial for both patients and healthcare providers. It not only aids in accurate diagnosis but also helps in monitoring disease progression and response to therapy. For those suspecting or managing an autoimmune condition, discussing Smith/RNP antibody testing with a healthcare professional can be an essential step in the journey towards better health management.

Smooth Muscle Antibodies (SMA), identified through the Immunofluorescence Assay (IFA), are pivotal in diagnosing autoimmune liver diseases, particularly Autoimmune Hepatitis (AIH). SMA-IFA testing detects antibodies targeting actin, a protein in smooth muscle cells, often found in patients with AIH. This test is crucial for differentiating AIH from other liver conditions like viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease. Positive SMA-IFA results, especially when combined with clinical findings and other laboratory tests, can significantly aid in confirming AIH. Early and accurate detection through SMA-IFA is essential for timely and effective treatment, reducing the risk of liver cirrhosis and liver failure. In the field of personalized healthcare, Smooth Muscle Abs, IFA testing is a key diagnostic tool, enhancing patient care through tailored treatment strategies for autoimmune liver diseases.

Autoimmune liver antibody

primarily associated with Sjögren’s syndrome

Autoantibody associated with SLE or Sjögren’s syndrome.

aid to diagnose autoimmune conditions

aid in diagnosing autoimmune conditions

Autoantibody associated with SLE or Sjögren’s syndrome.

single stranded DNA

Tacrolimus, Highly Sensitive, LC/MS/MS — Explanation for Lab Results Tacrolimus, Highly Sensitive (LC/MS/MS) is a laboratory test that measures the level of tacrolimus in the blood using a highly accurate and sensitive technique called Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS). Tacrolimus is an immunosuppressive drug primarily used to prevent organ rejection in patients who have undergone organ transplantation, such as kidney, liver, or heart transplants. It works by inhibiting the activity of the immune system to reduce the risk of rejecting the transplanted organ. Why is Tacrolimus Testing Important? Monitoring tacrolimus levels is crucial because its therapeutic window is narrow, meaning that small variations in blood concentration can lead to significant effects: Low levels may increase the risk of organ rejection. High levels can lead to toxic side effects, such as kidney damage (nephrotoxicity), neurological symptoms, or increased susceptibility to infections. The highly sensitive LC/MS/MS method provides greater accuracy and precision compared to traditional immunoassays, making it the preferred choice for detecting low concentrations and ensuring reliable monitoring.

a potent immunosuppressant widely used in organ transplantation

The TB1-NIL biomarker is integral to the QuantiFERON-TB Gold Plus (QFT-Plus) assay, a diagnostic tool used to detect Mycobacterium tuberculosis infection. In this context, 'NIL' refers to the baseline interferon-gamma (IFN-γ) level measured without antigen stimulation, serving as a negative control to account for non-specific background activity. The TB1 tube contains antigens that primarily stimulate CD4+ T-cell responses. By subtracting the NIL value from the TB1-stimulated IFN-γ level (TB1-NIL), clinicians can assess the specific immune response to TB antigens. A TB1-NIL value of 0.35 IU/mL or higher typically indicates a positive result, suggesting a TB infection. This method enhances the accuracy of TB diagnosis by distinguishing specific immune responses from background noise.

TB2-NIL Biomarker: Understanding Its Role and Clinical Significance What is TB2-NIL? TB2-NIL refers to the quantitative measurement of the difference between the TB Antigen 2 (TB2) response and the NIL response in the QuantiFERON-TB Gold test, a diagnostic test for latent tuberculosis infection (LTBI). This biomarker helps assess the immune response to Mycobacterium tuberculosis by measuring interferon-gamma (IFN-γ) levels. TB2: Represents the immune response to specific antigens associated with Mycobacterium tuberculosis. TB2 is more sensitive than TB1 because it also detects the response from central memory T cells, providing additional information in chronic or advanced cases. NIL: This is the baseline (negative control) level of IFN-γ without any stimulation. It helps account for non-specific background activity. A positive value suggests a specific immune response to TB antigens, indicating possible tuberculosis infection. A negative or low value generally suggests no specific immune response to TB. Clinical Use and Interpretation: Positive TB2-NIL: Indicates a heightened immune response to Mycobacterium tuberculosis. This is used to detect latent tuberculosis infection (LTBI). Negative TB2-NIL: Suggests the absence of a detectable immune response to tuberculosis antigens, ruling out LTBI or active TB infection. Why is TB2 Important? TB2, compared to TB1 (which only detects effector memory T cells), provides additional diagnostic sensitivity by capturing both effector and central memory T cell responses. This is particularly useful in immunocompromised patients or those with more chronic stages of tuberculosis. When is TB2-NIL Used? TB2-NIL is primarily used in: Screening for latent tuberculosis infection (LTBI) in high-risk populations. Monitoring tuberculosis infection in immunocompromised individuals, such as those with HIV or undergoing immunosuppressive therapy. Evaluating discordant or borderline TB1 responses, where TB2 can offer a clearer picture. Reference Range and Results: Negative: TB2-NIL < 0.35 IU/mL Positive: TB2-NIL ≥ 0.35 IU/mL and ≥ 25% greater than the NIL response Borderline or Indeterminate Results may occur due to technical variability or immune suppression and might require retesting.

a serious disease caused by the toxin from Clostridium tetani bacteria

Transforming Growth Factor (TGF)

What Is TNF-beta (Lymphotoxin-alpha)? TNF-beta, also called lymphotoxin-alpha, is a protein in the TNF superfamily that plays an important role in your immune system. It is primarily produced by activated T and B lymphocytes (types of white blood cells) and helps regulate inflammation, immune responses, and tumor immunity. How Does TNF-beta Work? Like TNF-alpha, TNF-beta signals through TNFR1 and TNFR2 receptors, which affect various processes in your body, including: Cell growth and repair (proliferation and differentiation). Cell death (apoptosis). Immune responses to infections and injuries. Although TNF-beta is similar to TNF-alpha, it has unique functions: Targeting tumor cells: TNF-beta can be more toxic to certain tumor cells, helping inhibit cancer development and promoting tumor shrinkage. Activating neutrophils (a type of immune cell). Triggering IL-1 release from endothelial cells to support inflammation. Stimulating fibroblasts to produce factors that help in wound healing. Why Is TNF-beta Important? This cytokine plays a role in both immune responses and inflammation by: Influencing antigen-specific immune activities. Promoting the expression of adhesion molecules. Supporting prostaglandin production (involved in inflammation). Maintaining chromosome integrity. What Do Abnormal TNF-beta Levels Mean? Elevated or dysregulated TNF-beta levels can contribute to health issues such as: Autoimmune diseases like rheumatoid arthritis or lupus. Chronic inflammatory conditions that cause ongoing damage to tissues and organs.

Transforming Growth Factor Beta 1 (TGF-β1) is a multifunctional cytokine playing a pivotal role in regulating a wide range of cellular processes, including cell growth, differentiation, apoptosis, and immune responses. As a member of the Transforming Growth Factor Beta superfamily of cytokines, TGF-β1 is particularly noted for its dual role in both promoting and inhibiting tumor formation. In normal physiological conditions, TGF-β1 functions as a critical regulator of tissue homeostasis, exerting potent anti-inflammatory and immunosuppressive effects. It helps maintain the balance in the immune system and prevents autoimmune responses. However, in the context of cancer, TGF-β1 has a more complex role. Initially, it acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis. But paradoxically, in the later stages of cancer, it can promote tumor progression and metastasis by inducing epithelial-to-mesenchymal transition (EMT), angiogenesis, and immune evasion. Furthermore, TGF-β1 is involved in fibrosis and wound healing, where it stimulates the deposition of extracellular matrix components. Aberrant regulation or expression of TGF-β1 is linked to various pathological conditions, including fibrotic diseases, cardiovascular diseases, and a spectrum of cancer types. Consequently, TGF-β1 serves as a crucial biomarker and a therapeutic target, with efforts being directed towards developing TGF-β1 inhibitors for treating cancer and other diseases characterized by its dysregulation. The complexity of TGF-β1's functions underscores its significance in cellular biology and disease pathogenesis, making it a focus of extensive research in the biomedical field.

a multifunctional peptide growth factor

Tryptase is released as part of a immune response

a protein in your body that causes inflammation and helps coordinate the process.

Determination of immune status of individuals to the varicella-zoster virus (VZV)

detection of Varicella zoster virus DNA in clinical specimens

a growth factor that promotes the growth of new blood vessels

VEGF, Serum – Vascular Endothelial Growth Factor What is VEGF? Vascular Endothelial Growth Factor (VEGF) is a family of proteins—most notably VEGF-A—that play a central role in stimulating the growth of new blood vessels, a process known as angiogenesis. VEGF is essential for normal physiological functions such as wound healing and the menstrual cycle, and it also contributes to disease processes including cancer, diabetic complications, and inflammatory disorders. Why is VEGF measured in serum? Measuring VEGF levels in the blood can help assess abnormal blood vessel growth and inflammation. This test is primarily used in clinical research and specialized medical settings to evaluate conditions where angiogenesis is either excessive or impaired. It is important to note that serum VEGF levels can be influenced by the release of VEGF from platelets during blood clotting. For this reason, some laboratories may prefer plasma measurements for research purposes to obtain more accurate readings. What do high VEGF levels mean? Elevated VEGF levels in serum may indicate: Cancer or tumor growth (such as breast, colon, or kidney cancers), where VEGF enables tumors to develop their own blood supply and potentially spread Autoimmune or inflammatory diseases (e.g., rheumatoid arthritis), where abnormal vessel growth and increased vascular permeability are common Diabetic complications, including retinopathy and nephropathy Chronic wounds or impaired tissue healing Preeclampsia during pregnancy What do low VEGF levels mean? Lower-than-normal VEGF levels may suggest: Impaired blood vessel formation, which can affect healing and tissue regeneration Poor circulation or compromised tissue repair Certain cardiovascular or neurodegenerative conditions, though low VEGF is less commonly used as a clinical marker Clinical relevance and therapeutic context VEGF testing is not part of routine health screening but is reserved for specific clinical or investigational purposes. VEGF levels can be affected by inflammation, low oxygen levels (hypoxia), and certain medications. Notably, anti-VEGF therapies—such as bevacizumab—are used in the treatment of cancers and some eye diseases to inhibit abnormal blood vessel growth. In oncology, VEGF measurements may help monitor disease progression or response to anti-angiogenic treatments. How to prepare for the test No special preparation is usually required for a VEGF serum test. However, your healthcare provider may advise you to avoid certain medications or supplements before the test to ensure accurate results. Summary VEGF is a key regulator of blood vessel growth, with important roles in both health and disease. Serum VEGF measurement can provide valuable insights in select clinical situations, particularly when abnormal angiogenesis is suspected. For more precise interpretation, discuss your results with a healthcare professional familiar with your medical history and current condition.

also called Ristocetin Cofactor

The von Willebrand Factor (VWF) Activity/VWF Antigen Ratio is a critical laboratory marker used in the diagnosis and evaluation of von Willebrand disease (VWD), a bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor, a protein essential for blood clotting. This ratio is particularly helpful in distinguishing between different types of VWD and in assessing the severity of the condition. What is the VWF Activity/VWF Antigen Ratio? The VWF Activity/VWF Antigen Ratio compares the functional activity of von Willebrand factor to its antigen level. The VWF activity refers to the protein's ability to support platelet adhesion to blood vessel walls, while the VWF antigen measures the quantity of the von Willebrand factor present in the blood. VWF Activity: Reflects how well von Willebrand factor is functioning to aid in blood clot formation. VWF Antigen: Reflects the amount of von Willebrand factor present in the bloodstream, regardless of whether it functions properly. This ratio is used to assess the balance between the quantity and function of von Willebrand factor. A normal ratio indicates that the activity and antigen levels are appropriately matched, while deviations from the norm suggest potential defects in the function or amount of von Willebrand factor. Clinical Significance Normal Range: The normal reference range for the VWF Activity/VWF Antigen Ratio is generally 0.7 to 1.0. Ratios within this range suggest that the von Willebrand factor is functioning normally. Low Ratio: A ratio below 0.7 can indicate a qualitative defect in von Willebrand factor, meaning that even though the quantity (antigen) of the protein may be normal, its ability to function (activity) is impaired. This is common in Type 2 von Willebrand disease, where a structural defect in the protein leads to reduced activity. High Ratio: Values above 1.0 are uncommon but can sometimes be seen in acquired conditions that alter the normal function of von Willebrand factor. This could suggest a shift toward an excess of functional protein, which may require further investigation. Role in Von Willebrand Disease Diagnosis The VWF Activity/VWF Antigen Ratio is invaluable for distinguishing between the various types of von Willebrand disease: Type 1 VWD: A mild quantitative deficiency of von Willebrand factor. The ratio typically remains normal (≥0.7), but both activity and antigen levels are lower than normal. Type 2 VWD: A qualitative defect in von Willebrand factor that impairs its function despite normal or near-normal antigen levels. The ratio is often below 0.7, particularly in Type 2A and Type 2M, and is critical for diagnosing these subtypes. Type 3 VWD: A severe deficiency of von Willebrand factor, often resulting in very low activity and antigen levels. The ratio can vary depending on the severity but is typically low. Interpretation of Results Healthcare providers interpret the VWF Activity/VWF Antigen Ratio in conjunction with other tests, including VWF multimer analysis, factor VIII levels, and clinical symptoms. The ratio helps determine the type of von Willebrand disease and guides appropriate treatment decisions, such as the use of desmopressin or clotting factor replacement therapies. Conclusion The VWF Activity/VWF Antigen Ratio is a vital diagnostic tool in the management of von Willebrand disease. It provides insights into both the quantity and functionality of von Willebrand factor, helping healthcare providers accurately diagnose and categorize the disease, ultimately guiding treatment strategies and improving patient care.

Von Willebrand Factor: Collagen Binding (vWF:CB) Assay The von Willebrand Factor: Collagen Binding (vWF:CB) assay is a sophisticated laboratory test that plays a crucial role in evaluating the functional capacity of von Willebrand factor (vWF), a multimeric glycoprotein essential for primary hemostasis. This test specifically assesses vWF's ability to bind to collagen, a critical step in the initial phase of blood clot formation. Mechanism and Significance The vWF:CB assay measures the affinity of vWF for collagen, the presence of high molecular weight vWF multimers, and the overall functional activity of vWF in platelet adhesion. The test simulates vWF's interaction with exposed collagen at sites of vascular injury and is particularly sensitive to the presence of large vWF multimers, which are most effective in platelet adhesion. Results are often expressed as a ratio of vWF:CB to vWF antigen (vWF:Ag). Clinical Applications The vWF:CB assay serves multiple clinical purposes, including diagnosing and subtyping von Willebrand Disease (VWD), especially type 2 variants; differentiating between quantitative and qualitative vWF defects; monitoring treatment efficacy in VWD patients; assessing acquired von Willebrand syndrome; and evaluating bleeding risks in surgical or clinical settings. Interpretation and Complementary Testing A reduced vWF:CB-to-vWF:Ag ratio (<0.7) suggests impaired vWF function. A normal ratio with low absolute values indicates a quantitative defect (Type 1 VWD), while a low ratio with normal or low absolute values suggests a qualitative defect (Type 2 VWD). The vWF:CB test is typically used alongside the vWF antigen (vWF:Ag) assay, Ristocetin cofactor activity (vWF:RCo) test, and Factor VIII coagulant activity (FVIII:C) measurement. Recent Advances and Future Directions Recent developments in vWF:CB testing include standardization efforts to improve inter-laboratory consistency, development of automated platforms for high-throughput testing, and exploration of novel collagen substrates to enhance specificity. Current research focuses on establishing more precise diagnostic cutoffs for VWD subtypes, investigating the role of vWF:CB in predicting cardiovascular events, and developing point-of-care testing options for rapid assessment in emergency settings. In conclusion, the vWF:CB assay provides critical insights into vWF functionality, serving as an indispensable tool in the comprehensive evaluation of hemostatic disorders. Its ability to detect subtle functional abnormalities makes it particularly valuable in the diagnosis and management of von Willebrand disease and related bleeding disorders.